



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/86, A61K 48/00, C12N 5/10, C12N 15/35		A3	(11) International Publication Number: (43) International Publication Date:	WO 00/28061 18 May 2000 (18.05.2000)
(21) International Application Number: (22) International Filing Date: 02 November 1999 (02.11.1999)		PCT/US99/25694 Published		
(30) Priority Data: 60/107,114 05 November 1998 (05.11.1998) US				
(60) Parent Application or Grant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [/]; O. WILSON, James, M. [/]; O. XIAO, Weidong [/]; O. WILSON, James, M. [/]; O. XIAO, Weidong [/]; O. KODROFF, Cathy, A. ; O.				
(54) Title: ADENO-ASSOCIATED VIRUS SEROTYPE 1 NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME (54) Titre: SEQUENCES D'ACIDE NUCLEIQUE DU SEROTYPE I DU VIRUS ASSOCIE AUX ADENOVIRUS, VECTEURS ET CELLULES HOTES CONTENANT CES DERNIERS				
(57) Abstract The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.				
(57) Abrégé L'invention concerne des séquences d'acide nucléique du sérotype 1 du virus associé aux adénovirus (AAV) ainsi que des vecteurs et des cellules hôtes contenant ces séquences et des fragments fonctionnels de ces derniers. L'invention traite également de procédés d'administration de gènes via des vecteurs dérivés de l'AAV-1.				

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/86, 15/35, 5/10, A61K 48/00		A3	(11) International Publication Number: WO 00/28061 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/25694		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 November 1999 (02.11.99)		(72) Inventors; and (73) Inventors/Applicants (for US only): WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). XIAO, Weidong [CN/US]; Apartment P4, 155 Washington Lane, Jenkintown, PA 19046 (US).	
(71) Applicant (for all designated States except US): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).		(82) Published <i>With international search report.</i> (88) Date of publication of the international search report: 3 August 2000 (03.08.00)	
(74) Agents: KODROFF, Cathy, A. et al.; Howson & Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).		(54) Title: ADENO-ASSOCIATED VIRUS SEROTYPE 1 NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME (57) Abstract <p>The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID
SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME

10 This work was supported by the National Institutes of Health, grant no. P30
DK47757-06 and PO1 HD32649-04. The US government may have certain rights in
5 this invention.

15

Field of the Invention

This invention relates generally to viral vector, and more particularly, to
recombinant viral vectors useful for gene delivery.

20

Background of the Invention

10 Adeno-associated viruses are small, single-stranded DNA viruses which
require helper virus to facilitate efficient replication [K.I. Berns, *Paroviridae: the*
25 *viruses and their replication*, p. 1007-1041, in F.N. Fields et al., Fundamental
virology, 3rd ed., vol. 2, (Lippencott-Raven Publishers, Philadelphia, PA) (1995)].
The 4.7 kb genome of AAV is characterized by two inverted terminal repeats (ITR)
30 and two open reading frames which encode the Rep proteins and Cap proteins,
respectively. The Rep reading frame encodes four proteins of molecular weight 78
kD, 68 kD, 52 kD and 40 kD. These proteins function mainly in regulating AAV
replication and integration of the AAV into a host cell's chromosomes. The Cap
35 reading frame encodes three structural proteins in molecular weight 85 kD (VP 1), 72
kD (VP2) and 61 kD (VP3) [Berns, cited above]. More than 80% of total proteins in
AAV virion comprise VP3. The two ITRs are the only cis elements essential for AAV
40 replication, packaging and integration. There are two conformations of AAV ITRs
called "flip" and "flop". These differences in conformation originated from the
replication model of adeno-associated virus which use the ITR to initiate and reinitiate
45 the replication [R.O. Snyder et al., *J. Virol.*, 67:6096-6104 (1993); K.I. Berns,
Microbiological Reviews, 54:316-329 (1990)].

35

40

45

50

AAVs have been found in many animal species, including primates, canine,
fowl and human [F.A. Murphy et al., "The Classification and Nomenclature of
Viruses: Sixth Report of the International Committee on Taxonomy of Viruses",

55

5

2

10 Archives of Virology, (Springer-Verlag, Vienna) (1995)]. In addition to five known
15 primate AAVs (AAV-1 to AAV-5), AAV-6, another serotype closely related to
AAV-2 and AAV-1 has also been isolated [E. A. Rutledge et al., J. Virol., 72:309-
319 (1998)]. Among all known AAV serotypes, AAV-2 is perhaps the most well-
5 characterized serotype, because its infectious clone was the first made [R.J. Samulski
et al., Proc. Natl. Acad. Sci. USA, 79:2077-2081 (1982)]. Subsequently, the full
20 sequences for AAV-3A, AAV-3B, AAV-4 and AAV-6 have also been determined
[Rutledge, cited above; J.A. Chiorini et al., J. Virol., 71:6823-6833 (1997); S.
Muramatsu et al., Virol., 221:208-217 (1996)]. Generally, all AAVs share more than
25 80% homology in nucleotide sequence.

25 A number of unique properties make AAV a promising vector for human gene therapy [Muzychka, Current Topics in Microbiology and Immunology, **158**:97-129 (1992)]. Unlike other viral vectors, AAVs have not been shown to be associated with any known human disease and are generally not considered pathogenic. Wild type

30 15 AAV is capable of integrating into host chromosomes in a site specific manner [R. M. Kotin et al., Proc. Natl. Acad. Sci. USA, **87**:2211-2215 (1990)- R.J. Samulski, EMBO J., **10**(12):3941-3950 (1991)]. Recombinant AAV vectors can integrate into tissue cultured cells in chromosome 19 if the rep proteins are supplied in *trans* [C. Balague et al., J. Virol., **71**:3299-3306 (1997); R. T. Surosky et al., J. Virol.,

35 20 **71**:7951-7959 (1997)]. The integrated genomes of AAV have been shown to allow long term gene expression in a number of tissues, including, muscle, liver, and brain [K. J. Fisher, Nature Med., **3**(3):306-312 (1997); R. O. Snyder et al., Nature Genetics, **16**:270-276 (1997); X. Xiao et al., Experimental Neurology, **144**:113-124 (1997); Xiao, J. Virol., **70**(11):8098-8108 (1996)].

40 25 AAV-2 has been shown to be present in about 80-90% of the human population. Earlier studies showed that neutralizing antibodies for AAV-2 are prevalent [W. P. Parks et al., J. Virol., **2**:716-722 (1970)]. The presence of such antibodies may significantly decrease the usefulness of AAV vectors based on AAV-2 despite its other merits. What are needed in the art are vectors characterized by the

45

50

55

60

65

70

75

80

85

90

95

55

5

3

10 advantages of AAV-2, including those described above, without the disadvantages, including the presence of neutralizing antibodies.

Summary of the Invention

15 In one aspect, the invention provides an isolated AAV-1 nucleic acid molecule
5 which is selected from among SEQ ID NO: 1, the strand complementary to SEQ ID
NO: 1, and cDNA and RNA sequences complementary to SEQ ID NO: 1 and its
complementary strand.

20 In another aspect, the present invention provides AAV ITR sequences, which
include the 5' ITR sequences, nt 1 to 143 of SEQ ID NO: 1; the 3' ITR sequences, nt
10 4576 to 4718 of SEQ ID NO: 1, and fragments thereof.

25 In yet another aspect, the present invention provides a recombinant vector
comprising an AAV-1 ITR and a selected transgene. Preferably, the vector comprises
both the 5' and 3' AAV-1 ITRs between which the selected transgene is located.

30 In still another aspect, the invention provides a recombinant vector comprising
35 15 an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1 or a
functional fragment thereof.

35 In a further aspect, the present invention provides a nucleic acid molecule
encoding an AAV-1 rep coding region and an AAV-1 cap coding region.

40 In still another aspect, the present invention provides a host cell transduced with a
20 recombinant viral vector of the invention. The invention further provides a host cell
stably transduced with an AAV-1 P5 promoter of the invention.

45 In still a further aspect, the present invention provides a pharmaceutical
composition comprising a carrier and a vector of the invention.

50 In yet another aspect, the present invention provides a method for AAV--
45 mediated delivery of a transgene to a host involving the step of delivering to a selected
host a recombinant viral vector comprising a selected transgene under the control of
sequences which direct expression thereof and an adeno-associated virus 1 (AAV-1)
virion.

5

4

10 In another aspect, the invention provides a method for in vitro production of a selected gene product using a vector of the invention.

15 Other aspects and advantages of the invention will be readily apparent to one of skill in the art from the detailed description of the invention.

15

5 **Brief Description of the Drawings**

20 Figs. 1A-1C illustrate the alignment of nucleotides of AAV-1 [SEQ ID NO: 1], AAV-2 [SEQ ID NO: 18] and AAV-6 [SEQ ID NO: 19]. The alignment was done with MacVector 6.0. The full sequences of AAV-1 are shown in the top line. Nucleotides in AAV-2 and AAV-6 identical to AAV-1 are symbolized by "." and gaps 10 by "-". Some of the conserved features among AAVs are marked in this figure. Note 25 the 3' ITRs of AAV-1 and AAV-6 are shown in different orientations.

Fig. 2 illustrates the predicted secondary structure of AAV-1 ITR. The nucleotides in AAV-2 and AAV-6 are shown in italic and bold respectively.

30 Fig. 3A illustrates a hypothesis of how AAV-6 arose from the homologous 15 recombination between AAV-1 and AAV-2. The major elements of AAV-1 are indicated in the graph. A region that is shared between AAV-1, AAV-2 and AAV-6 is 20 shown in box with waved lines.

35 Fig. 3B is a detailed illustration of a 71 bp homologous region among AAV-1, AAV-2 and AAV-6. Nucleotides that differ among these serotypes are indicated by 20 arrows.

40 Fig. 4A is a bar chart illustrating expression levels of human alpha 1 anti- 25 trypsin (α 1AT) in serum following delivery of hAAAT via recombinant AAV-1 and recombinant AAV-2 viruses.

45 Fig. 4B is a bar chart illustrating expression levels of erythropoietin (epo) in 25 serum following delivery of the epo gene via recombinant AAV-1 and recombinant AAV-2 viruses.

50 Fig. 5A is a bar chart illustrating expression levels of α 1AT in liver following delivery of α 1AT as described in Example 7.

5

5

10 Fig. 5B is a bar chart demonstrating expression levels of epo in liver following delivery of epo as described in Example 7.

Fig. 5C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of α 1AT or epo to liver as described in Example 7.

15 Fig. 5D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of α 1AT or epo to liver as described in Example 7.

Fig. 6A is a bar chart illustrating expression levels of α 1AT in muscle following delivery of α 1AT as described in Example 7.

20 Fig. 6B is a bar chart demonstrating expression levels of epo in muscle following delivery of epo as described in Example 7.

Fig. 6C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of α 1AT or epo to muscle as described in Example 7.

25 Fig. 6D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of α 1AT or epo to muscle as described in Example 7.

30 15 **Detailed Description of the Invention**

The present invention provides novel nucleic acid sequences for an adeno-associated virus of serotype 1 (AAV-1). Also provided are fragments of these AAV-1 sequences. Among particularly desirable AAV-1 fragments are the inverted terminal repeat sequences (ITRs), rep and cap. Each of these fragments may be readily utilized, e.g., as a cassette, in a variety of vector systems and host cells. Such fragments may be used alone, in combination with other AAV-1 sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences. In one particularly desirable embodiment, a cassette may contain the AAV-1 ITRs of the invention flanking a selected transgene. In another desirable embodiment, a cassette may contain the AAV-1 rep and/or cap proteins, e.g., for use in producing recombinant (rAAV) virus.

40 25 Thus, the AAV-1 sequences and fragments thereof are useful in production of rAAV, and are also useful as antisense delivery vectors, gene therapy vectors, or 45 vaccine vectors. The invention further provides nucleic acid molecules, gene delivery

5

6

10 vectors, and host cells which contain the AAV-1 sequences of the invention. Also provided a novel methods of gene delivery using AAV vectors.

15 As described herein, the vectors of the invention containing the AAV-1 capsid proteins of the invention are particularly well suited for use in applications in which the neutralizing antibodies diminish the effectiveness of other AAV serotype based vectors, as well as other viral vectors. The rAAV vectors of the invention are particularly advantageous in rAAV readministration and repeat gene therapy.

20 These and other embodiments and advantages of the invention are described in more detail below. As used throughout this specification and the claims, the term 10 "comprising" is inclusive of other components, elements, integers, steps and the like.

25 **I. AAV-1 NUCLEIC ACID AND PROTEIN SEQUENCES**

30 The AAV-1 nucleic acid sequences of the invention include the DNA sequences of SEQ ID NO: 1 (Figs. 1A-1C), which consists of 4718 nucleotides. The AAV-1 nucleic acid sequences of the invention further encompass the strand which is 35 complementary to SEQ ID NO: 1, as well as the RNA and cDNA sequences corresponding to SEQ ID NO: 1 and its complementary strand. Also included in the nucleic acid sequences of the invention are natural variants and engineered 40 modifications of SEQ ID NO: 1 and its complementary strand. Such modifications include, for example, labels which are known in the art, methylation, and substitution 20 of one or more of the naturally occurring nucleotides with an analog.

45 Further included in this invention are nucleic acid sequences which are greater than 85%, preferably at least about 90%, more preferably at least about 95%, and most preferably at least about 98 - 99% identical or homologous to SEQ ID NO:1.

50 The term "percent sequence identity" or "identical" in the context of nucleic acid 45 sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over the full-length sequence, or a fragment at least about nine nucleotides, usually at least about 20 - 24 nucleotides, at least about 28 - 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different

5

7

algorithms known in the art which can be used to measure nucleotide sequence
10 identity. For instance, polynucleotide sequences can be compared using Fasta, a
program in GCG Version 6.1. Fasta provides alignments and percent sequence
identity of the regions of the best overlap between the query and search sequences
15 (Pearson, 1990, herein incorporated by reference). For instance, percent sequence
identity between nucleic acid sequences can be determined using Fasta with its default
parameters (a word size of 6 and the NOPAM factor for the scoring matrix) as
provided in GCG Version 6.1, herein incorporated by reference.

20

The term "substantial homology" or "substantial similarity," when referring to
10 a nucleic acid or fragment thereof, indicates that, when optimally aligned with
appropriate nucleotide insertions or deletions with another nucleic acid (or its
25 complementary strand), there is nucleotide sequence identity in at least about 95 -
99% of the sequence.

25

Also included within the invention are fragments of SEQ ID NO: 1, its
30 complementary strand, cDNA and RNA complementary thereto. Suitable fragments
are at least 15 nucleotides in length, and encompass functional fragments which are of
biological interest. Certain of these fragments may be identified by reference to Figs.
35 1A-1C. Examples of particularly desirable functional fragments include the AAV-1
inverted terminal repeat (ITR) sequences of the invention. In contrast to the 145 nt
40 ITRs of AAV-2, AAV-3, and AAV-4, the AAV-1 ITRs have been found to consist of
only 143 nucleotides, yet advantageously are characterized by the T-shaped hairpin
45 structure which is believed to be responsible for the ability of the AAV-2 ITRs to
direct site-specific integration. In addition, AAV-1 is unique among other AAV
serotypes, in that the 5' and 3' ITRs are identical. The full-length 5' ITR sequences of
50 AAV-1 are provided at nucleotides 1-143 of SEQ ID NO: 1 (Fig. 1A) and the full-
length 3' ITR sequences of AAV-1 are provided at nt 4576-4718 of SEQ ID NO: 1
(Fig. 1C). One of skill in the art can readily utilize less than the full-length 5' and/or 3'
55 ITR sequences for various purposes and may construct modified ITRs using
conventional techniques, e.g., as described for AAV-2 ITRs in Samulski et al, Cell,
30 33:135-143 (1983).

55

5

8

Another desirable functional fragment of the AAV-1 genome is the P5 promoter of AAV-1 which has sequences unique among AAV P5 promoters, while maintaining critical regulatory elements and functions. This promoter is located within nt 236 - 299 of SEQ ID NO: 1 (Fig. 1A). Other examples of functional fragments of interest include the sequences at the junction of the rep/cap, e.g., the sequences spanning nt 2306-2223, as well as larger fragments which encompass this junction which may comprise 50 nucleotides on either side of this junction. Still other examples of functional fragments include the sequences encoding the rep proteins. Rep 78 is located in the region of nt 334 - 2306 of SEQ ID NO: 1; Rep 68 is located in the region of nt 334-2272, and contains an intron spanning nt 1924-2220 of SEQ ID NO: 1. Rep 52 is located in the region of nt 1007 - 2304 of SEQ ID NO: 1; rep 40 is located in the region of nt 1007 - 2272, and contains an intron spanning nt 1924-2246 of SEQ ID NO: 1. Also of interest are the sequences encoding the capsid proteins, VP 1 [nt 2223-4431 of SEQ ID NO: 1], VP2 [nt 2634-4432 of SEQ ID NO: 1] and VP3 [nt 2829-4432 of SEQ ID NO: 1]. Other fragments of interest may include the AAV-1 P19 sequences, AAV-1 P40 sequences, the rep binding site, and the terminal resolute site (TRS).

The invention further provides the proteins and fragments thereof which are encoded by the AAV-1 nucleic acids of the invention. Particularly desirable proteins include the rep and cap proteins, which are encoded by the nucleotide sequences identified above. These proteins include rep 78 [SEQ ID NO:5], rep 68 [SEQ ID NO:7], rep 52 [SEQ ID NO:9], rep 40 [SEQ ID NO: 11], vpl [SEQ ID NO: 13], vp2 [SEQ ID NO: 15], and vp3 [SEQ ID NO: 17] and functional fragments thereof while the sequences of the rep and cap proteins have been found to be closely related to those of AAV-6, there are differences in the amino acid sequences (see Table 1 below), as well as differences in the recognition of these proteins by the immune system. However, one of skill in the art may readily select other suitable proteins or protein fragments of biological interest. Suitably, such fragments are at least 8 amino acids in length. However, fragments of other desired lengths may be readily utilized.

50

55

5

9

Such fragments may be produced recombinantly or by other suitable means, e.g.,
10 chemical synthesis.

15 The sequences, proteins, and fragments of the invention may be produced by any suitable means, including recombinant production, chemical synthesis, or other synthetic means. Such production methods are within the knowledge of those of skill in the art and are not a limitation of the present invention.

II. VIRAL VECTORS

20 In another aspect, the present invention provides vectors which utilize the AAV-1 sequences of the invention, including fragments thereof, for delivery of a
10 heterologous gene or other nucleic acid sequences to a target cell. Suitably, these heterologous sequences (i.e., a transgene) encode a protein or gene product which is capable of being expressed in the target cell. Such a transgene may be constructed in the form of a "minigene". Such a "minigene" includes selected heterologous gene sequences and the other regulatory elements necessary to transcribe the gene and
25 express the gene product in a host cell. Thus, the gene sequences are operatively linked to regulatory components in a manner which permit their transcription. Such components include conventional regulatory elements necessary to drive expression of the transgene in a cell containing the viral vector. The minigene may also contain a selected promoter which is linked to the transgene and located, with other regulatory
30 elements, within the selected viral sequences of the recombinant vector.

35 Selection of the promoter is a routine matter and is not a limitation of this invention. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the timing and amount of the transgene to be expressed. For example, desirable promoters include the cytomegalovirus (CMV)
40 immediate early promoter/enhancer [see, e.g., Boshart et al, *Cell*, 41:521-530 (1985)],
45 the Rous sarcoma virus LTR promoter/enhancer, and the chicken cytoplasmic β -actin promoter [T. A. Kost et al, *Nucl. Acids Res.*, 11(23):8287 (1983)]. Still other desirable promoters are the albumin promoter and an AAV P5 promoter. Optionally,
50 the selected promoter is used in conjunction with a heterologous enhancer, e.g., the β -

5

10

actin promoter may be used in conjunction with the CMV enhancer. Yet other
10 suitable or desirable promoters and enhancers may be selected by one of skill in the
art.

15 The minigene may also desirably contain nucleic acid sequences heterologous
5 to the viral vector sequences including sequences providing signals required for
efficient polyadenylation of the transcript (poly-A or pA) and introns with functional
splice donor and acceptor sites. A common poly-A sequence which is employed in
the exemplary vectors of this invention is that derived from the papovavirus SV-40.
20 The poly-A sequence generally is inserted in the minigene downstream of the
10 transgene sequences and upstream of the viral vector sequences. A common intron
sequence is also derived from SV-40, and is referred to as the SV40 T intron
sequence. A minigene of the present invention may also contain such an intron,
25 desirably located between the promoter/enhancer sequence and the transgene.
Selection of these and other common vector elements are conventional [see, e.g.,
15 Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d edit., Cold Spring
30 Harbor Laboratory, New York (1989) and references cited therein] and many such
sequences are available from commercial and industrial sources as well as from
Genebank.

35 The selection of the transgene is not a limitation of the present invention.
20 Suitable transgenes may be readily selected from among desirable reporter genes,
therapeutic genes, and optionally, genes encoding immunogenic polypeptides.
40 Examples of suitable reporter genes include β -galactosidase (β -gal), an alkaline
phosphatase gene, and green fluorescent protein (GFP). Examples of therapeutic
genes include, cytokines, growth factors, hormones, and differentiation factors,
45 among others. The transgene may be readily selected by one of skill in the art. See,
e.g., WO 98/09657, which identifies other suitable transgenes.

50 Suitably, the vectors of the invention contain, at a minimum, cassettes which
5 consist of fragments of the AAV-1 sequences and proteins. In one embodiment, a
vector of the invention comprises a selected transgene, which is flanked by a 5' ITR
30 and a 3' ITR, at least one of which is an AAV-1 ITR of the invention. Suitably,

5

11

10

vectors of the invention may contain a AAV-1 P5 promoter of the invention. In yet another embodiment, a plasmid or vector of the invention contains AAV-1 rep sequences. In still another embodiment, a plasmid or vector of the invention contains at least one of the AAV-1 cap proteins of the invention. Most suitably, these AAV-1-derived vectors are assembled into viral vectors, as described herein.

15

5 A. AAV Viral Vectors

20

In one aspect, the present invention provides a recombinant AAV-1 viral vector produced using the AAV-1 capsid proteins of the invention. The packaged rAAV-1 virions of the invention may contain, in addition to a selected minigene, other AAV-1 sequences, or may contain sequences from other AAV serotypes.

25

Methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, *J. Virol.*, 70:520-532 (1993) and US Patent 5,478,745. In one suitable method, a selected host cell is provided with the AAV sequence encoding a rep protein, the gene encoding the AAV cap protein and with the sequences for packaging and subsequent delivery. Desirably, the method utilizes the sequences encoding the AAV-1 rep and/or cap proteins of the invention.

35

In one embodiment, the rep/cap genes and the sequences for delivery are supplied by co-transfection of vectors carrying these genes and sequences. In one currently preferred embodiment, a cis (vector) plasmid, a trans plasmid containing the rep and cap genes, and a plasmid containing the adenovirus helper genes are co-transfected into a suitable cell line, e.g., 293. Alternatively, one or more of these functions may be provided in trans via separate vectors, or may be found in a suitably engineered packaging cell line.

45

An exemplary cis plasmid will contain, in 5' to 3' order, AAV 5' ITR, the selected transgene, and AAV 3' ITR. In one desirable embodiment, at least one of the AAV ITRs is a 143 nt AAV-1 ITR. However, other AAV serotype ITRs may be readily selected. Suitably, the full-length ITRs are utilized. However, one of skill in

50

55

5

12

the art can readily prepare modified AAV ITRs using conventional techniques.
10 Similarly, methods for construction of such plasmids is well known to those of skill in the art.

15 A trans plasmid for use in the production of the rAAV-1 virion particle may be prepared according to known techniques. In one desired embodiment, this plasmid contains the rep and cap proteins of AAV-1, or functional fragments thereof. Alternatively, the rep sequences may be from another selected AAV serotype.

20 The cis and trans plasmid may then be co-transfected with a wild-type helper virus (e.g., Ad2, Ad5, or a herpesvirus), or more desirably, a replication - defective adenovirus, into a selected host cell. Alternatively, the cis and trans plasmid may be co-transfected into a selected host cell together with a transfected plasmid 25 which provides the necessary helper functions. Selection of a suitable host cell is well within the skill of those in the art and include such mammalian cells as 293 cells, HeLa cells, among others.

30 15 Alternatively, the cis plasmid and, optionally the trans plasmid, may be transfected into a packaging cell line which provides the remaining helper functions necessary for production of a rAAV containing the desired AAV-1 sequences of the invention. An example of a suitable packaging cell line, where an AAV-2 capsid is 35 desired, is B-50, which stably expresses AAV-2 rep and cap genes under the control 20 of a homologous P5 promoter. This cell line is characterized by integration into the cellular chromosome of multiple copies (at least 5 copies) of P5-rep-cap gene 40 cassettes in a concatomer form. This B-50 cell line was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, on September 18, 1997 under Accession No. CRL-12401 pursuant to the 45 provisions of the Budapest Treaty. However, the present invention is not limited as to the selection of the packaging cell line.

50 55 Exemplary transducing vectors based on AAV-1 capsid proteins have been tested both *in vivo* and *in vitro*, as described in more detail in Example 4. In 30 these studies, it was demonstrated that recombinant AAV vector with an AAV-1 virion can transduce both mouse liver and muscle. These, and other AAV-1 based

10 gene therapy vectors which may be generated by one of skill in the art are beneficial
for gene delivery to selected host cells and gene therapy patients since the
neutralization antibodies of AAV-1 present in much of the human population exhibit
different patterns from other AAV serotypes and therefore do not neutralize the
15 5 AAV-1 virions. One of skill in the art may readily prepare other rAAV viral vectors
containing the AAV-1 capsid proteins provided herein using a variety of techniques
known to those of skill in the art. One may similarly prepare still other rAAV viral
vectors containing AAV-1 sequence and AAV capsids of another serotype.

20

B. Other Viral Vectors

25

10 One of skill in the art will readily understand that the AAV-1
sequences of the invention can be readily adapted for use in these and other viral
vector systems for *in vitro*, *ex vivo* or *in vivo* gene delivery. Particularly well suited
for use in such viral vector systems are the AAV-1 ITR sequences, the AAV-1 rep,
the AAV-1 cap, and the AAV-1 P5 promoter sequences.

30

15 For example, in one desirable embodiment, the AAV-1 ITR sequences
of the invention may be used in an expression cassette which includes AAV-1 5' ITR,
a non-AAV DNA sequences of interest (e.g., a minigene), and 3' ITR and which lacks
functional rep/cap. Such a cassette containing an AAV-1 ITR may be located on a
35 plasmid for subsequent transfection into a desired host cell, such as the *cis* plasmid
20 described above. This expression cassette may further be provided with an AAV
capsid of a selected serotype to permit infection of a cell or stably transfected into a
desired host cell for packaging of rAAV virions. Such an expression cassette may be
readily adapted for use in other viral systems, including adenovirus systems and
40 lentivirus systems. Methods of producing Ad/AAV vectors are well known to those
25 of skill in the art. One desirable method is described in PCT/US95/14018. However,
the present invention is not limited to any particular method.

45

Another aspect of the present invention is the novel AAV-1 P5
50 promoter sequences which are located in the region spanning nt 236 - 299 of SEQ ID
NO: 1. This promoter is useful in a variety of viral vectors for driving expression of a
30 desired transgene.

5

14

Similarly, one of skill in the art can readily select other fragments of the
10 AAV-1 genome of the invention for use in a variety of vector systems. Such vectors
systems may include, e.g., lentiviruses, retroviruses, poxviruses, vaccinia viruses, and
adenoviral systems, among others. Selection of these vector systems is not a
15 limitation of the present invention.

5 C. Host Cells And Packaging Cell Lines

In yet another aspect, the present invention provides host cells which
20 may be transiently transfected with AAV-1 nucleic acid sequences of the invention to
permit expression of a desired transgene or production of a rAAV particle. For
10 example, a selected host cell may be transfected with the AAV-1 P5 promoter
sequences and/or the AAV-1 5' ITR sequences using conventional techniques.
25 Providing AAV helper functions to the transfected cell lines of the invention results in
packaging of the rAAV as infectious rAAV particles. Such cell lines may be produced
in accordance with known techniques [see, e.g. US Patent No. 5,658,785], making
15 use of the AAV-1 sequences of the invention.

30 Alternatively, host cells of the invention may be stably transfected with
a rAAV expression cassette of the invention, and with copies of AAV-1 rep and cap
genes. Suitable parental cell lines include mammalian cell lines and it may be desirable
35 to select host cells from among non-simian mammalian cells. Examples of suitable
parental cell lines include, without limitation, HeLa [ATCC CCL 2], A549 [ATCC
20 Accession No. CCL 185], KB [CCL 17], Detroit [e.g., Detroit 510, CCL 72] and WI-
38 [CCL 75] cells. These cell lines are all available from the American Type Culture
40 Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 USA. Other
suitable parent cell lines may be obtained from other sources and may be used to
25 construct stable cell lines containing the P5 and/or AAV rep and cap sequences of the
invention.

45 Recombinant vectors generated as described above are useful for
delivery of the DNA of interest to cells.

50

55

III. METHODS OF DELIVERING GENES VIA AAV-1 DERIVED VECTORS

10

In another aspect, the present invention provides a method for delivery of a transgene to a host which involves transfecting or infecting a selected host cell with a recombinant viral vector generated with the AAV-1 sequences (or functional fragments thereof) of the invention. Methods for delivery are well known to those of skill in the art and are not a limitation of the present invention.

15

In one desirable embodiment, the invention provides a method for AAV-mediated delivery of a transgene to a host. This method involves transfecting or infecting a selected host cell with a recombinant viral vector containing a selected transgene under the control of sequences which direct expression thereof and AAV-1 capsid proteins.

20

Optionally, a sample from the host may be first assayed for the presence of antibodies to a selected AAV serotype. A variety of assay formats for detecting neutralizing antibodies are well known to those of skill in the art. The selection of such an assay is not a limitation of the present invention. See, e.g., Fisher et al, *Nature Med.*, 3(3):306-312 (March 1997) and W. C. Manning et al, *Human Gene Therapy*, 9:477-485 (March 1, 1998). The results of this assay may be used to determine which AAV vector containing capsid proteins of a particular serotype are preferred for delivery, e.g., by the absence of neutralizing antibodies specific for that capsid serotype.

25

In one aspect of this method, the delivery of vector with AAV-1 capsid proteins may precede or follow delivery of a gene via a vector with a different serotype AAV capsid protein. Thus, gene delivery via rAAV vectors may be used for repeat gene delivery to a selected host cell. Desirably, subsequently administered rAAV vectors carry the same transgene as the first rAAV vector, but the subsequently administered vectors contain capsid proteins of serotypes which differ from the first vector. For example, if a first vector has AAV-2 capsid proteins, subsequently administered vectors may have capsid proteins selected from among the other serotypes, including AAV-1, AAV-3A, AAV-3B, AAV-4 and AAV-6.

30

35

40

45

50

5

16

10 Thus, a rAAV-1-derived recombinant viral vector of the invention provides an
efficient gene transfer vehicle which can deliver a selected transgene to a selected host
cell *in vivo* or *ex vivo* even where the organism has neutralizing antibodies to one or
more AAV serotypes. These compositions are particularly well suited to gene
15 delivery for therapeutic purposes. However, the compositions of the invention may
also be useful in immunization. Further, the compositions of the invention may also
be used for production of a desired gene product *in vitro*.

20 The above-described recombinant vectors may be delivered to host cells
according to published methods. An AAV viral vector bearing the selected transgene
10 may be administered to a patient, preferably suspended in a biologically compatible
solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle includes
25 sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and
aqueous and non-aqueous sterile suspensions known to be pharmaceutically
acceptable carriers and well known to those of skill in the art may be employed for
15 this purpose.

30 The viral vectors are administered in sufficient amounts to transfect the cells
and to provide sufficient levels of gene transfer and expression to provide a
therapeutic benefit without undue adverse effects, or with medically acceptable
35 physiological effects, which can be determined by those skilled in the medical arts.
20 Conventional and pharmaceutically acceptable routes of administration include, but
are not limited to, direct delivery to the liver, oral, intranasal, intravenous,
intramuscular, subcutaneous, intradermal, and other parental routes of administration.
40 Routes of administration may be combined, if desired.

45 Dosages of the viral vector will depend primarily on factors such as the
condition being treated, the age, weight and health of the patient, and may thus vary
among patients. For example, a therapeutically effective human dosage of the viral
vector is generally in the range of from about 1 ml to about 100 ml of solution
50 containing concentrations of from about 1×10^9 to 1×10^{16} genomes virus vector. A
preferred human dosage may be about 1×10^{13} to 1×10^{16} AAV genomes. The
30 dosage will be adjusted to balance the therapeutic benefit against any side effects and

such dosages may vary depending upon the therapeutic application for which the recombinant vector is employed. The levels of expression of the transgene can be monitored to determine the frequency of dosage resulting in viral vectors, preferably AAV vectors containing the minigene. Optionally, dosage regimens similar to those described for therapeutic purposes may be utilized for immunization using the compositions of the invention. For *in vitro* production, a desired protein may be obtained from a desired culture following transfection of host cells with a rAAV containing the gene encoding the desired protein and culturing the cell culture under conditions which permits expression. The expressed protein may then be purified and isolated, as desired. Suitable techniques for transfection, cell culturing, purification, and isolation are known to those of skill in the art.

The following examples illustrate several aspects and embodiments of the invention.

Example 1 - Generation of Infectious Clone of AAV-1

The replicated form DNA of AAV-1 was extracted from 293 cells that were infected by AAV-1 and wild type adenovirus type 5.

A. Cell Culture and Virus

AAV-free 293 cells and 84-31 cells were provided by the human application laboratory of the University of Pennsylvania. These cells were cultured in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum (Hyclone), penicillin (100 U/ml) and streptomycin at 37°C in a moisturized environment supplied with 5% CO₂. The 84-31 cell line constitutively expresses adenovirus genes E1a, E1b, E4/ORF6, and has been described previously [K. J. Fisher, J. Virol., **70**:520-532 (1996)]. AAV-1 (ATCC VR-645) seed stock was purchased from American Type Culture Collection (ATCC, Manassas, VA). AAV viruses were propagated in 293 cells with wild type Ad5 as a helper virus.

B. Recombinant AAV Generation

The recombinant AAV viruses were generated by transfection using an adenovirus free method. Briefly, the cis plasmid (with AAV ITR), trans plasmid (with

5

18

AAV rep gene and cap gene) and helper plasmid (pF Δ 13, with essential regions from
10 the adenovirus genome) were simultaneously co-transfected into 293 cells in a ratio of
1:1:2 by calcium phosphate precipitation. The pF Δ 13 helper plasmid has an 8 kb
15 deletion in the adenovirus E2B region and has deletions in most of the late genes.

5 This helper plasmid was generated by deleting the RsrII fragment from pFG140
(Microbix, Canada). Typically, 50 μ g of DNA (cis:trans:pF Δ 13 at ratios of 1:1:2,
10 respectively) was transfected onto a 15 cm tissue culture dish. The cells were
harvested 96 hours post-transfection, sonicated and treated with 0.5% sodium
20 deoxycholate (37°C for 10 min). Cell lysates were then subjected to two rounds of a
25 CsCl gradient. Peak fractions containing AAV vector were collected, pooled, and
dialyzed against PBS before injecting into animals. To make rAAV virus with AAV-1
virion, the pAV1H or p5E18 (2/1) was used as the *trans* plasmid to provide rep and
cap function.

For the generation of rAAV based on AAV-2, p5E18 was used as the
30 *trans* plasmid since it greatly improved the rAAV yield. This plasmid, p5E18(2/2),
expresses AAV-2 Rep and Cap and contains a P5 promoter relocated to a position 3'
35 to the Cap gene, thereby minimizing expression of Rep78 and Rep68. The strategy
was initially described by Li et al, *J. Virol.*, 71:5236-5243 (1997). P5E18(2/2) was
constructed in the following way. The previously described pMMTV-trans vector
40 (i.e., the mouse mammary tumor virus promoter substituted for the P5 promoter in an
AAV-2-based vector) was digested with *Sma*I and *Cla*I, filled in with the Klenow
enzyme, and then recircularized with DNA ligase. The resulting construct was
45 digested with *Xba*I, filled in, and ligated to the blunt-ended *Bam*HI-*Xba*I fragment
from pCR-p5, constructed in the following way. The P5 promoter of AAV was
50 amplified by PCR and the amplified fragment was subsequently cloned into pCR2.1
(Invitrogen) to yield pCR-P5. The helper plasmid pAV1H was constructed by cloning
the *Bfa*I fragment of pAAV-2 into pBluescript II-SK(+) at the *Bco*V and *Sma*I sites.
The 3.0-kb *Xba*I-*Kpn*I fragment from p5E18(2/2), the 2.3-kb *Xba*I-*Kpn*I fragment
55 from pAV1H, and the 1.7-kb *Kpn*I fragment from p5E18(2/2) were incorporated into
a separate plasmid P5E18(2/1), which contains AAV-2 Rep, AAV-1 Cap, and the

5

19

AAV-2 P5 promoter located 3' to the Cap gene. Plasmid pSE18(2/1) produced 10- to
10 20-fold higher quantities of the vector than pAV1H (i.e., 10¹² genomes/50 15-cm²
plates).

15 C. DNA Techniques

5 Hirt DNA extraction was performed as described in the art with minor
modification [R.J. Samulski et al., *Cell*, 33:135-143 (1983)]. More particularly, Hirst
solution without SDS was used instead of using original Hirst solution containing SDS.
The amount of SDS present in the original Hirst solution was added after the cells had
20 been fully suspended. To construct AAV-1 infectious clone, the Hirt DNA from
10 AAV-1 infected 293 cells was repaired with Klenow enzyme (New England Biolabs)
to ensure the ends were blunt. The treated AAV-1 Hirt DNA was then digested with
25 *BamHI* and cloned into three vectors, respectively. The internal *BamHI* was cloned
into pBlueScript II-SK+ cut with *BamHI* to get pAV1-BM. The left and right
fragments were cloned into pBlueScript II-SK+ cut with *BamHI* + EcoRV to obtain
15 pAV1-BL and pAV1-BR, respectively. The AAV sequence in these three plasmids
30 were subsequently assembled into the same vector to get AAV-1 infectious clone
pAAV-1. The helper plasmid for recombinant AAV-1 virus generation was
constructed by cloning the *Bfa I* fragment of pAAV-1 into pBlueScript II-SK+ at the
35 EcoRV site.
20 Analysis of the Hirt DNA revealed three bands, a dimer at 9.4 kb, a
monomer at 4.7 kb and single-stranded DNA at 1.7 kb, which correlated to different
40 replication forms of AAV-1. The monomer band was excised from the gel and then
digested with *BamHI*. This resulted in three fragments of 1.1 kb, 0.8 kb and 2.8 kb.
This pattern is in accordance with the description by Bantel-schaal and zur Hausen,
25 *Virol.*, 134(1):52-63 (1984). The 1.1 kb and 2.8 kb *BamHI* fragments were cloned
45 into pBlueScript-KS(+) at *BamHI* and EcoRV site. The internal 0.8 kb fragment was
cloned into *BamHI* site of pBlueScript-KS(+).
50 These three fragments were then subcloned into the same construct to
55 obtain a plasmid (pAAV-1) that contained the full sequence of AAV-1. The pAAV-1
30 was then tested for its ability to rescue from the plasmid backbone and package

55

5

20

10 infectious virus. The pAAV-1 was then transfected to 293 cells and supplied with adenovirus type as helper at MOI 10. The virus supernatant was used to reinfect 293 cells.

15 For Southern blot analysis, Hirt DNA was digested with *Dpn*I to remove bacteria-borne plasmid and probed with internal *Bam*H I fragment of AAV-1. The membrane was then washed at high stringency conditions, which included: twice 30 minutes with 2X SSC, 0.1% SDS at 65°C and twice 30 minutes with 0.1X SSC, 0.1% SDS at 65°C. The membrane was then analyzed by both phosphor image and 20 X-ray autoradiography. The results confirmed that pAAV-1 is indeed an infectious 10 clone of AAV serotype 1.

25 Example 2 - Sequencing Analysis of AAV-1

The entire AAV-1 genome was then determined by automatic sequencing and was found to be 4718 nucleotides in length (Figs. 1A-1C). For sequencing, an ABI 373 automatic sequencer as used to determine the sequences for all plasmids and PCR 30 fragments related to this study using the FS dye chemistry. All sequences were confirmed by sequencing both plus and minus strands. These sequences were also confirmed by sequencing two independent clones of pAV-BM, pAV-BL and pAV- 35 BR. Since the replicated form of AAV-1 DNA served as the template for sequence determination, these sequences were also confirmed by sequencing a series of PCR 20 products using original AAV-1 seed stock as a template.

40 The length of AAV-1 was found to be within the range of the other serotypes: AAV-3 (4726 nucleotides), AAV-4 (4774 nucleotides), AAV-2 (4681 nucleotides), and AAV-6 (4683 nucleotides).

45 The AAV-1 genome exhibited similarities to other serotypes of adeno- 25 associated viruses. Overall, it shares more than 80% identity with other known AAV viruses as determined by the computer program Megalign using default settings [DNASTAR, Madison, WI]. The key features in AAV-2 can also be found in AAV- 50 1. First, AAV-1 has the same type of inverted terminal repeat which is capable of forming T-shaped hairpin structures, despite the differences at the nucleotide level

5

21

(Figs. 2 and 3). The sequences of right ITRs and left ITRs of AAV-1 are identical.
10 The AAV TR sequence is subdivided into A, A', B, B', C, C', D and D' [Bern, cited above].

These AAV ITR sequences are also virtually the same as those found in AAV-
15 6 right ITR, there being one nucleotide difference in each of A and A' sequence, and the last nucleotide of the D sequence. Second, the AAV-2 rep binding motif [GCTCGCTCGCTCGCTG (SEQ ID NO: 20)] is well conserved. Such motif can also be found in the human chromosome 19 AAV-2 pre-integration region. Finally, 20 non-structural and structural coding regions, and regulatory elements similar to those of other AAV serotypes also exist in AAV-1 genome.

Although the overall features of AAV terminal repeats are very much conserved, the total length of the AAV terminal repeat exhibits divergence. The 25 terminal repeat of AAV-1 consists of 143 nucleotides while those of AAV-2, AAV-3, and AAV-4 are about 145 or 146 nucleotides. The loop region of AAV-1 ITR most 30 closely resembles that of AAV-4 in that it also uses TCT instead of the TTT found in AAV-2 and AAV-3. The possibility of sequencing error was eliminated using restriction enzyme digestion, since these three nucleotides are part of the SacI site (gagctc; nt 69-74 of SEQ ID NO: 1). The p5 promoter region of AAV-1 shows more 35 variations in nucleotide sequences with other AAV serotypes. However, it still 40 maintains the critical regulatory elements. The two copies of YY1 [See, Fig. 1A-1C] sites seemed to be preserved in all known AAV serotypes, which have been shown to be involved in regulating AAV gene expression. In AAV-4, there are 56 additional nucleotides inserted between YY1 and E-box/USF site, while in AAV-1, there are 26 additional nucleotides inserted before the E-box/USF site. The p19 promoter, p40 45 promoter and polyA can also be identified from the AAV-1 genome by analogy to known AAV serotypes, which are also highly conserved.

Thus, the analysis of AAV terminal repeats of various serotypes showed that the A and A' sequence is very much conserved. One of the reasons may be the Rep 50 binding motif (GCTC),GCTG [SEQ ID NO: 20]. These sequences appear to be essential for AAV DNA replication and site-specific integration. The same sequence

5

22

has also been shown to be preserved in a monkey genome [Samulski, personal communication]. The first 8 nucleotides of the D sequence are also identical in all known AAV serotypes. This is in accordance with the observation of the Srivastava group that only the first 10 nucleotides are essential for AAV packaging [X.S. Wang et al, *J. Virol.*, **71**:3077-3082 (1997); X.S. Wang et al, *J. Virol.*, **71**:1140-1146 (1997)]. The function of the rest of the D sequences still remain unclear. They may be somehow related to their tissue specificities. The variation of nucleotide in B and C sequence may also suggest that the secondary structure of the ITRs is more critical for its biological function, which has been demonstrated in many previous publications.

25 **Example 3 - Comparison of AAV-1 Sequences**

The nucleotide sequences of AAV-1, obtained as described above, were compared with known AAV sequences, including AAV-2, AAV-4 and AAV-6 using DNA Star Megalign. This comparison revealed a stretch of 71 identical nucleotides shared by AAV-1, AAV-2 and AAV-6. See, Figs. 1A-1C.

30 15 This comparison further suggested that AAV-6 is a hybrid formed by homologous recombination of AAV-1 and AAV-2. See, Figs. 3A and 3B. These 35 nucleotides divide the AAV-6 genome into two regions. The 5' half of AAV-6 of 522 nucleotides is identical to that of AAV-2 except in 2 positions. The 3' half of AAV-6 20 including the majority of the rep gene, complete cap gene and 3' ITR is 98% identical to AAV-1.

40 45 Biologically, such recombination may enable AAV-1 to acquire the ability to transmit through the human population. It is also interesting to note that the ITRs of AAV-6 comprise one AAV-1 ITR and one AAV-2 ITR. The replication model of defective parvovirus can maintain this special arrangement. Studies on AAV 50 integration have shown that a majority of AAV integrants carries deletions in at least one of the terminal repeats. These deletions have been shown to be able to be repaired through gene conversion using the other intact terminal repeat as a template. Therefore, it would be very difficult to maintain AAV-6 as a homogenous population

5

23

when an integrated copy of AAV-6 is rescued from host cells with helper virus
10 infection. The AAV-6 with two identical AAV-2 ITRs or two identical AAV-1 ITRs
should be the dominant variants. The AAV-6 with two AAV-1 ITRs has been
15 observed by Russell's group [Rutledge, cited above (1998)]. So far there is no report
on AAV-6 with two AAV-2 ITRs. Acquisition of AAV-2 P5 promoter by AAV-6
may have explained that AAV-6 have been isolated from human origin while AAV-1
with the same virion has not. The regulation of P5 promoter between different
20 species of AAV may be different *in vivo*. This observation suggests the capsid
proteins of AAV were not the only determinants for tissue specificity.

10 Although it is clear that AAV-6 is a hybrid of AAV-1 and AAV-2, AAV-6 has
already exhibited divergence from either AAV-1 or AAV-2. There are two nucleotide
25 differences between AAV-6 and AAV-2 in their first 450 nucleotides. There are
about 1% differences between AAV-6 and AAV-1 in nucleotide levels from
nucleotides 522 to the 3' end. There also exists a quite divergent region (nucleotide
15 4486-4593) between AAV-6 and AAV-1 (Figs. 1A-1C). This region does not
30 encode any known proteins for AAVs. These differences in nucleotide sequences may
suggest that AAV-6 and AAV-1 have gone through some evolution since the
recombination took place. Another possible explanation is that there exists another
35 variant of AAV-1 which has yet to be identified. So far, there is no evidence to rule
20 out either possibility. It is still unknown if other hybrids (AAV-2 to AAV-4, etc.)
existed in nature.

40 The coding region of AAV-1 was deduced by comparison with other known
AAV serotypes. Table 1 illustrates the coding region differences between AAV-1 and
AAV-6. The amino acid residues are deduced according to AAV-2.

45 25 With reference to the amino acid position of AAV-1, Table 1 lists the amino
acids of AAV-1 which have been changed to the corresponding ones of AAV-6. The
amino acids of AAV-1 are shown to the left of the arrow. Reference may be made to
SEQ ID NO: 5 of the amino acid sequence of AAV-1 Rep 78 and to SEQ ID NO: 13
50 for the amino acid sequence of AAV-1 VP1.

5

24

Table 1

10

Coding region variations between AAV-1 and AAV-6

15

5

20

Rep protein (Rep78)		Cap protein (VP1)	
Position(s)	Amino acids	Position(s)	Amino acids
28	S-N	129	L-F
191	Q-H	418	E-D
192	H-D	531	E-K
308	E-D	584	F-L
		598	A-V
		642	N-H

25

30

35

It was surprising to see that the sequence of the AAV-1 coding region is almost identical to that of AAV-6 from position 452 to the end of coding region (99%). The first 508 nucleotides of AAV-6 have been shown to be identical to those of AAV-2 [Rutledge, cited above (1998)]. Since the components of AAV-6 genome seemed to be AAV-2 left ITR - AAV-2 p5 promoter - AAV-1 coding region - AAV-1 right ITR, it was concluded that AAV-6 is a naturally occurred hybrid between AAV-1 and AAV-2.

40

45

50

Example 4 - Gene Therapy Vector Based on AAV-1

Recombinant gene transfer vectors based on AAV-1 viruses were constructed by the methods described in Example 1. To produce a hybrid recombinant virus with AAV-1 virion and AAV-2 ITR, the AAV-1 trans plasmid (pAV1H) and the AAV-2 cis-lacZ plasmid (with AAV-2 ITR) were used. The AAV-2 ITR was used in this vector in view of its known ability to direct site-specific integration. Also constructed for use in this experiment was an AAV-1 vector carrying the green fluorescent protein (GFP) marker gene under the control of the immediate early promoter of CMV using pAV1H as the trans plasmid.

55

5

25

A. rAAV-1 Viruses Transfect Host Cells in Vitro

10

84-31 cells, which are subclones of 293 cells (which express adenovirus E1a, E1b) which stably express E4/ORF5, were infected with rAAV-1 GFP or rAAV-lacZ. High levels of expression of GFP and lacZ was detected in the cultured 84-31 cells. This suggested that rAAV-1 based vector was very similar to AAV-2 based vectors in ability to infect and expression levels.

15

B. rAAV-1 Viruses Transfect Cells in Vivo

20

The performance of AAV-1 based vectors was also tested *in vivo*. The rAAV-1 CMV- α 1AT virus was constructed as follows. The EcoRI fragment of pAT85 (ATCC) containing human α 1-antitrypsin (α 1AT) cDNA fragment was blunted and cloned into PCR (Promega) at a SmaI site to obtain PCR- α 1AT. The CMV promoter was cloned into PCR- α 1AT at the XbaI site. The Alb- α 1AT expression cassette was removed by XbaI and ClaI and cloned into pAV1H at the XbaI site. This vector plasmid was used to generate AAV-1-CMV- α 1AT virus used in the experiment described below.

25

For screening human antibodies against AAV, purified AAV virus is lysed with Ripa buffer (10 mM Tris pH 8.2, 1% Triton X-100, 1% SDS, 0.15 M NaCl) and separated in 10% SDS-PAGE gel. The heat inactivated human serum was used at a 1 to 1000 dilution in this assay. The rAAV-1 CMV- α 1AT viruses were injected into Rag-1 mice through tail vein injection at different dosages. The concentration of human α 1-antitrypsin in mouse serum was measured using ELISA. The coating antibody is rabbit anti-human human α 1-antitrypsin (Sigma). The goat-antihuman α 1-antitrypsin (Sigma) was used as the primary detection antibodies. The sensitivity of this assay is around 0.3 ng/ml to 30 ng/ml. The expression of human α -antitrypsin in mouse blood can be detected in a very encouraging level. This result is shown in Table 2.

30

35

40

45

50

55

5

26

Table 2

10

Human Antitrypsin Expressed in Mouse Liver

15

	Amount of virus injected	Week 2 (ng/ml)	Week 4 (ng/ml)
	2×10^{10} genomes	214.2	171.4
5	1×10^{10} genomes	117.8	109.8
	5×10^{10} genomes	64.5	67.8
	2.5×10^{10} genomes	30.9	58.4

20

rAAV-1 CMV-lacZ viruses were also injected into the muscle of C57BL6 mice and similar results were obtained. Collectively, these results suggested that AAV-1 based vector would be appropriate for both liver and muscle gene delivery.

25

30

Example 5 - Neutralizing Antibodies Against AAV-1

35

Simple and quantitative assays for neutralizing antibodies (NAB) to AAV-1 and AAV-2 were developed with recombinant vectors. A total of 33 rhesus monkeys and 77 normal human subjects were screened.

40

A. *Nonhuman Primates*

45

Wild-caught juvenile rhesus monkeys were purchased from Covance (Alice, Tex.) and LABS of Virginia (Yemassee, SC) and kept in full quarantine. The monkeys weighed approximately 3 to 4 kg. The nonhuman primates used in the Institute for Human Gene Therapy research program are purposefully bred in the United States from specific-pathogen-free closed colonies. All vendors are US Department of Agriculture class A dealers. The rhesus macaques are therefore not infected with important simian pathogens, including the tuberculosis agent, major simian lentiviruses (simian immunodeficiency virus and simian retroviruses), and cercopithecine herpesvirus. The animals are also free of internal and external parasites. The excellent health status of these premium animals minimized the potential for extraneous variables. For this study, serum was obtained from monkeys prior to initiation of any protocol.

50

55

5

27

10 NAB titers were analyzed by assessing the ability of serum antibody to
inhibit the transduction of reporter virus expressing green fluorescent protein (GFP)
(AAV1-GFP or AAV2-GFP) into 84-31 cells. Various dilutions of antibodies
15 preincubated with reporter virus for 1 hour at 37°C were added to 90% confluent cell
cultures. Cells were incubated for 48 hours and the expression of green fluorescent
protein was measured by FluoroImaging (Molecular Dynamics). NAB titers were
calculated as the highest dilution at which 50% of the cells stained green.

20 Analysis of NAB in rhesus monkeys showed that 61% of animals
tested positive for AAV-1; a minority (24%) has NAB to AAV-2. Over one-third of
10 animals had antibodies to AAV-1 but not AAV-2 (i.e., were monospecific for AAV-
1), whereas no animals were positive for AAV-2 without reacting to AAV-1. These
25 data support the hypothesis that AAV-1 is endemic in rhesus monkeys. The presence
of true AAV-2 infections in this group of nonhuman primates is less clear, since cross-
neutralizing activity of an AAV-1 response to AAV-2 can not be ruled out. It is
15 interesting that there is a linear relationship between AAV-2 NAB and AAV-1 NAB
30 in animals that had both.

B. *Humans*

35 For these neutralization antibody assays, human serum samples were
incubated at 56°C for 30 min to inactivate complement and then diluted in DMEM.
20 The virus (rAAV or rAd with either lacZ or GFP) was then mixed with each serum
dilution (20X, 400X, 2000X, 4000X, etc.) and incubated for 1 hour at 37°C before
40 applied to 90% confluent cultures of 84-31 cells (for AAV) or Hela cells (for
adenovirus) in 96-well plates. After 60 minutes of incubation at culture condition,
25 100 µl additional media containing 20% FCS was added to make final culture media
containing 10% FCS.

45

50

55

5

28

The result is summarized in Table 3.

10

Table 3

Adenovirus	AAV-1	AAV-2	# of samples	Percentage
-	-	-	41	53.2%
+	-	-	16	20.8%
-	+	-	0	0.0%
-	-	+	2	2.6%
-	+	+	2	2.6%
+	-	+	3	3.9%
+	+	-	0	0.0%
+	+	+	13	16.9%
Total			77	100%

30

The human neutralizing antibodies against these three viruses seemed to be unrelated since the existence of neutralizing antibodies against AAV are not indications for antibodies against adenovirus. However, AAV requires adenovirus as helper virus, in most of the cases, the neutralizing antibodies against AAV correlated with the existence of neutralizing antibodies to adenovirus. Among the 77 human serum samples screened, 41% of the samples can neutralize the infectivity of recombinant adenovirus based on Ad5. 15/77 (19%) of serum samples can neutralize the transduction of rAAV-1 while 20/77 (20%) of the samples inhibit rAAV-2 transduction at 1 to 80 dilutions or higher. All serum samples positive in neutralizing antibodies for AAV-1 are also positive for AAV-2. However, there are five (6%) rAAV-2 positive samples that failed to neutralize rAAV-1. In samples that are positive for neutralizing antibodies, the titer of antibodies also varied in the positive ones. The results from screening human sera for antibodies against AAVs supported the conclusion that AAV-1 presents the same epitome as that of AAV-2 to interact

50

55

5

29

10 with cellular receptors since AAV-1 neutralizing human serums can also decrease the infectivity of AAV-2. However, the profile of neutralizing antibodies for these AAVs is not identical, there are additional specific receptors for each AAV serotype.

15 **Example 6 - Recombinant AAV Viruses Exhibit Tissue Tropism**

20 5 The recombinant AAV-1 vectors of the invention and the recombinant AAV-2 vectors [containing the gene encoding human α 1-antitrypsin (α 1AT) or murine erythropoietin (Epo) from a cytomegalovirus-enhanced β -actin promoter (CB)] were evaluated in a direct comparison to equivalent copies of AAV-2 vectors containing the same vector genes.

25 10 Recombinant viruses with AAV-1 capsids were constructed using the techniques in Example 1. To make rAAV with AAV-1 virions, pAV1H or p5E18 (2/1) was used as the *trans* plasmid to provide Rep and Cap functions. For the generation of the rAAV based on AAV-2, p5E18(2/2) was used as the *trans* plasmid, since it greatly improved the rAAV yield. [Early experiments indicated similar *in vivo* 30 15 performances of AAV-1 vectors produced with pAV1H and p5E19 (2/1). All subsequent studies used AAV-1 vectors derived from p5E18(2/1) because of the increased yield.]

35 20 Equivalent stocks of the AAV-1 and AAV-2 vectors were injected intramuscularly (5×10^{10} genomes) or liver via the portal circulation (1×10^{11} genomes) into immunodeficient mice, and the animals (four groups) were analyzed on day 30 for expression of transgene. See, Figs. 4A and 4B.

40 25 45 AAV-2 vectors consistently produced 10- to 50-fold more serum erythropoietin or α 1-antitrypsin when injected into liver compared to muscle. (However, the AAV-1-delivered genes did achieve acceptable expression levels in the liver.) This result was very different from that for AAV-1 vectors, with which muscle expression was equivalent to or greater than liver expression. In fact, AAV-1 outperformed AAV-2 in muscle when equivalent titers based on genomes were administered.

50

55

5

30

Example 7 - Gene Delivery via rAAV-1

10

C57BL/6 mice (6- to 8-week old males, Jackson Laboratories) were analyzed for AAV mediated gene transfer to liver following intrasplenic injection of vector (i.e., targeted to liver). A total of 10^{11} genome equivalents of rAAV-1 or rAAV-2 vector were injected into the circulation in 100 μ l buffered saline. The first vector contained either an AAV-1 capsid or an AAV-2 capsid and expressed α 1AT under the control of the chicken β -actin (CB) promoter. Day 28 sera were analyzed for antibodies against AAV-1 or AAV-2 and serum α 1AT levels were checked. Animals were then injected with an AAV-1 or AAV-2 construct expressing erythropoietin (Epo, also under the control of the CB promoter). One month later sera was analyzed for serum levels of Epo. The following groups were analyzed (Figs. 5A-5D).

25

In Group 1, vector 1 was AAV-2 expressing α 1AT and vector 2 was AAV-2 expressing Epo. Animals generated antibodies against AAV-2 following the first vector administration which prevented the readministration of the AAV-2 based vector. There was no evidence for cross-neutralizing the antibody to AAV-1.

30

In Group 2, vector 1 was AAV-1 expressing α 1AT while vector 2 was AAV-1 expressing Epo. The first vector administration did result in significant α 1AT expression at one month associated with antibodies to neutralizing antibodies to AAV-1. The animals were not successfully readministered with the AAV-1 Epo expressing construct.

40

In Group 3, the effectiveness of an AAV-2 vector expressing Epo injected into a naive animal was measured. The animals were injected with PBS and injected with AAV-2 Epo vector at day 28 and analyzed for Epo expression one month later. The neutralizing antibodies were evaluated at day 28 so we did not expect to see anything since they received PBS with the first vector injection. This shows that in naive animals AAV-2 is very efficient at transferring the Epo gene as demonstrated by high level of serum Epo one month later.

45

Group 4 was an experiment similar to Group 3 in which the animals originally received PBS for vector 1 and then the AAV-1 expressing Epo construct 28 days later. At the time of vector injection, there obviously were no antibodies to either

50

55

5

31

AAV-1 or AAV-2. The AAV-1 based vector was capable of generating significant
10 expression of Epo when measured one month later.

Group 5 is a cross-over experiment where the initial vector is AAV-2
expressing α 1AT followed by the AAV-1 construct expressing Epo. The animals, as
15 expected, were efficiently infected with the AAV-2 vector expressing α 1AT as shown
by high levels of the protein in blood at 28 days. This was associated with significant
neutralizing antibodies to AAV-2. Importantly, the animals were successfully
administered AAV-1 following the AAV-2 vector as shown by the presence of Epo in
20 serum 28 days following the second vector administration. At the time of this vector
administration, there was high level AAV-2 neutralizing antibodies and very low
cross-reaction to AAV-1. The level of Epo was slightly diminished possibly due to a
25 small amount of cross-reactivity. Group 6 was the opposite cross-over experiment in
which the initial vector was AAV-1 based, whereas the second experiment was AAV-
2 based. The AAV-1 vector did lead to significant gene expression of α 1AT, which
30 also resulted in high level AAV-1 neutralizing antibody. The animals were very
efficiently administered AAV-2 following the initial AAV-1 vector as evidenced by
high level Epo.

A substantially identical experiment was performed in muscle in which 5×10^{10}
35 genomes were injected into the tibialis anterior of C57BL/6 mice as a model for
20 muscle directed gene therapy. The results are illustrated in Figs. 6A-6D and are
essentially the same as for liver.

In summary, this experiment demonstrates the utility of using an AAV-1
40 vector in patients who have pre-existing antibodies to AAV-2 or who had initially
received an AAV-2 vector and readministration.

45 25 Example 8 - Construction of Recombinant Viruses Containing AAV-1 ITRs

This example illustrates the construction of recombinant AAV vectors which
contain AAV-1 ITRs of the invention.

An AAV-1 cis plasmid is constructed as follows. A 160 bp Xho-NruI AAV-1
50 fragment containing the AAV-1 5' ITR is obtained from pAV1-BL. pAV1-BL was

55

5

32

10

generated as described in Example 1. The Xho-NruI fragment is then cloned into a second pAV1-BL plasmid at an XbaI site to provide the plasmid with two AAV-1 ITRs. The desired transgene is then cloned into the modified pAV-1BL at the NruI and BamHI site, which is located between the AAV-1 ITR sequences. The resulting 5 AAV-1 cis plasmid contains AAV-1 ITRs flanking the transgene and lacks functional AAV-1 rep and cap.

15

20

Recombinant AAV is produced by simultaneously transfecting three plasmids into 293 cells. These include the AAV-1 cis plasmid described above; a trans plasmid which provides AAV rep/cap functions and lacks AAV ITRs; and a plasmid providing 10 adenovirus helper functions. The rep and/or cap functions may be provided in trans by AAV-1 or another AAV serotype, depending on the immunity profile of the intended recipient. Alternatively, the rep or cap functions may be provided in cis by 25 AAV-1 or another serotype, again depending on the patient's immunity profile.

25

30

35

In a typical cotransfection, 50 µg of DNA (cis:trans:helper at ratios of 1:1:2, 15 respectively) is transfected onto a 15 cm tissue culture dish. Cells are harvested 96 hours post transfection, sonicated and treated with 0.5% sodium deoxycholate (37° for 10 min). Cell lysates are then subjected to 2-3 rounds of ultracentrifugation in a cesium gradient. Peak fractions containing rAAV are collected, pooled and dialyzed against PBS. A typical yield is 1×10^{13} genomes/10⁹ cells.

40

20 Using this method, one recombinant virus construct is prepared which contains the AAV-1 ITRs flanking the transgene, with an AAV-1 capsid. Another recombinant virus construct is prepared with contains the AAV-1 ITRs flanking the transgene, with an AAV-2 capsid.

50

All publications cited in this specification are incorporated herein by reference.

45

25 While the invention has been described with reference to a particularly preferred embodiments, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the claims.

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

33

What is claimed is:

10

1. An isolated AAV-1 nucleic acid molecule comprising a sequence selected from the group consisting of:

15

- (a) SEQ ID NO: 1;
- (b) a DNA sequence complementary to SEQ ID NO: 1;
- (c) cDNA complementary to (a) or (b); and
- (d) RNA complementary to any of (a) to (c).

20

2. A nucleic acid molecule comprising an AAV-1 inverted terminal repeat (ITR) sequence selected from the group consisting of:

25

- (a) nt 1 to 143 of SEQ ID NO: 1;
- (b) nt 4576 to 4718 of SEQ ID NO: 1;
- (c) a nucleic acid sequence complementary to (a) or (b); and
- (d) a functional fragment of (a), (b), or (c).

30

35

3. A recombinant vector comprising a 5' AAV-1 inverted terminal repeat (ITR) and a selected transgene, wherein said ITR has the sequence selected from the group consisting of:

- (a) nt 1 to 143 of SEQ ID NO: 1;
- (b) a nucleic acid sequence complementary to (a); and
- (c) a functional fragment of (a) or (b).

40

4. The recombinant vector according to claim 3, wherein said vector further comprises a 3' AAV-1 ITR.

45

50

55

5

34

5. A recombinant vector comprising a 3' AAV-1 inverted terminal repeat (ITR) and a selected transgene, wherein said ITR has the sequence selected from the group consisting of:

10 (a) nt 4576 to 4718 of SEQ ID NO: 1;
15 (b) a nucleic acid sequence complementary to (a); and
(c) a functional fragment of (a) or (b).

20 6. The recombinant vector according to claim 5, wherein said vector further comprises a 5' AAV-1 ITR.

25 7. The recombinant vector according to any of claims 3-6, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 or functional fragments thereof.

30 8. The recombinant vector according to any of claims 3-6, wherein said vector further comprises adenovirus sequences.

35 9. A recombinant vector comprising an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1 or a functional fragment thereof.

40 10. A nucleic acid molecule encoding AAV-1 helper functions, said molecule comprising an AAV rep coding region and an AAV cap coding region, wherein said cap coding region comprises at least one member is selected from the group consisting of:

45 (a) vp1, nt 2223 to 4431 of SEQ ID NO: 1;
(b) vp2, nt 2634 to 4432 of SEQ ID NO: 1; and
(c) vp3, nt 2829 to 4432 of SEQ ID NO: 1.

50

55

5

35

10 11. A nucleic acid molecule encoding AAV-1 helper functions, said molecule comprising an AAV rep coding region and an AAV cap coding region, wherein said rep coding region comprises an AAV-1 rep coding region comprising at least one member selected from the group consisting of:

15 (a) rep 78, nt 335 to 2304 of SEQ ID NO: 1;
(b) rep 68, nt 335 to 2272 of SEQ ID NO: 1 or the cDNA corresponding thereto;
20 (c) rep 52, nt 1007 to 2304 of SEQ ID NO: 1; and
(d) rep 40, nt 1007 to 2272 of SEQ ID NO: 1 or the cDNA corresponding thereto.

25 12. A host cell transduced with a recombinant viral vector according to any of claims 3-6.

30 13. A host cell transduced with a nucleic acid molecule according to any of claims 1, 2, 10 or 11.

35 14. A host cell stably transduced with an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1.

40 15. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to any of claims 3-6.

45 16. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 7.

50 17. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 8.

55

5

36

18. A method for AAV-mediated delivery of a transgene comprising the
10 step of delivering to a host cell an AAV virion which comprises:

- (a) a capsid comprising at least one capsid protein encoded by an
AAV-1 cap gene; and
- (b) a DNA molecule comprising a transgene under the control of
15 regulatory sequences directing its expression.

19. A method for AAV-mediated delivery of a transgene to a host
20 comprising the steps of:

- (a) assaying a sample from the host to determine the presence of
neutralizing antibodies specific against any serotype of AAV; and
- (b) delivering to the host an AAV virion which comprises:
 - (i) a capsid comprising at least one capsid protein encoded
by a cap gene of an AAV serotype against which the host has no antibodies as
determined in step (a); and
 - (ii) a DNA molecule comprising a transgene under the
control of regulatory sequences directing its expression.

20. The method according to claim 19, comprising the additional step of
35 repeating steps (a) and (b).

21. Use of an AAV virion which comprises a capsid comprising (a) at
40 least one capsid protein encoded by a cap gene of an AAV serotype against which the
host has antibodies, and (b) a DNA molecule comprising a transgene operably linked
to regulatory sequences directing its expression,

45 in the preparation of a medicament for delivery of a transgene to a
host, wherein said host has no preexisting neutralizing antibodies against the AAV
serotype of said cap gene.

50

55

5

37

22. A method for delivery of a transgene comprising the step of delivering
10 to a host cell a recombinant virus comprising a recombinant vector according to any
of claims 3-8.

15 23. A method for producing a selected gene product comprising the steps
of transfecting a mammalian cell with the molecule according to claim 1 or a
functional fragment thereof and culturing said cell under conditions suitable to express
said gene product.

20

25

30

35

40

45

50

55

1/13

FIG 1A

AAV-1	ttgcccactccctctgcgcgctcgctcgctcggtgggcctgcggaccaaaggccgc	60	
AAV-2	...g.....ac..a...g.gc.....gc.	60	
AAV-6	...g.....ac..a...g.gc.....gc.	60	
	<u>Rep binding site</u>		
AAV-1	agacggcagagctctgctctggccaccgagcgcagcgccagagagggagtg	120	
AAV-2	c....c.c.g....t....c.g.g....t....gt.....	120	
AAV-6	c....c.c.g....t....c.g.g....t....gt.....	120	
	<u>TRS</u>		
AAV-1	ggcaactccatcaactagggtaaTCGCGAAGCGCTCCCACGCTGCCGCTCAGCGCTGA	180	
AAV-2	.c.....-..ct.G..G.....TG.A...G-----	163	
AAV-6	.c.....-..ct.G..G.....TG.A...G-----	163	
	<u>E box/USF</u>		
AAV-1	CGTAAATTACGTCAAGGG---GAGTGGTCCTGTATTAGCTGTCACGTGAGTGCTTTGC	237	
AAV-2	...G.....TTA.G.A.....AG.....	222	
AAV-6	...G.....TTA.G.A.....AG.....	222	
	<u>YY1</u>	<u>PS/TATA</u>	
AAV-1	GACATTGCGACACCACGTGGCATTAGGTATATGGCGAGTGAGCGAGCAGGAT	297	
AAV-2T....T..CGCT.....T..A.C.....AC.....G.	282	
AAV-6T....T..CGCT.....T..A.C.....AC.....G.	282	
	<u>YY1/p5 RNA</u>	<u>Rep 78/68</u>	
AAV-1	CTCCATTGAC-CGCGAAATTGAAACGAGCAGCAGCCATGCCGGCTCTACGAGATCG	356	
AAV-2AG..G..GG.....C.....C.....G..T.....T.	342	
AAV-6AG..G..GG.....C.....C.....G..T.....T.	341	
	AAV-1	TGATCAAGGTGCCGAGCGACCTGGACGAGCACCTGCCGGCATTTCTGACTCGTTGTGA	416
AAV-2T.....C..C.....T....G..T.....C.....AGC.....	402	
AAV-6T.....C..C.....T....T.....C.....AGC.....	401	
	AAV-1	GCTGGGTGCCGAGAGGAATGGGAGCTGCCCGGATTCTGACATGGATCTGAATCTGA	476
AAV-2	A.....T....G..A.....	462	
AAV-6	A.....T....G..A.....	461	
	AAV-1	TTGAGCAGGCACCCCTGACCGTGGCGAGAAGCTGCAGCGCAGCTCTGGTCCAATGGC	536
AAV-2T.....T.....ACGG.....	522	
AAV-6T.....G.....	521	
	AAV-1	GCCCGTGAGTAAGGCCCGAGGCCCTCTCTTGTTCAGTCGAGAAGGGCGAGTCCT	596
AAV-2T.....T.....G..A..T.....A..AG..	582	
AAV-6T.....T.....G..A..T.....A..AG..	581	
	AAV-1	ACTTCCACCTCCATATTCTGGAGACCACGGGGTCAAATCCATGGTCTGGCGCT	656
AAV-2A.G..CG..G..C.....A.....G.....TT.....A..T..	642	
AAV-6A.....G.....TT.....A..T..	641	
	AAV-1	TCCTGAGTCAGATTAGGGACAAGCTGGTGCAGACCATCTACCGCGGGATCGAGCCGACCC	716
AAV-2C..C..A..A..A..T..GA..T.....TT	702	
AAV-6C..C..A..A..A..T..GA..T.....TT	701	
	AAV-1	TGCCCAACTGGTCGCGGTGACCAAGACGCGTAATGGCGCCGGAGGGGGAAACAAGGTGG	776
AAV-2A.....C..A.....CA..A.....C.....	762	
AAV-6A.....C..A.....CA..A.....C.....	761	

2/13

FIG 1B

AAV-1	TGGACGAGTGCTACATCCCCAACTACCTCCTGCCAAGACTCAGCCCGAGCTGCAGTGGG	836
AAV-2T.....T.....T.G..C.....A..C.....T.....C.....	822
AAV-6C.....G.....A.....G.....A..C..GG.C.....	821
	P19/TATA	P19 RNA
AAV-1	CGTGGACTAACATGGAGGAGTATATAAGCGCCTGTTGAACCTGGCCGAGCGCAAACGGC	896
AAV-2T.....AC.....T.....C.....G..T..CA.G.....T.....T	882
AAV-6C.....GG.....A.....G.....A..C..GG.C.....	881
AAV-1	TCGTGGCCGAGCACCTGACCCACGTCAAGCCAGACCCAGGAGCAGAACAAGGAGAATCTGA	956
AAV-2	.G.....T.....G.....GTGCG.....G.....A.....A..	942
AAV-6CG.....	941
	Rep 52/40	
AAV-1	ACCCCAATTCTGACGCCCTGTCATCCGTCAAAACCTCCGCGCCTACATGGAGCTGG	1016
AAV-2	.T.....T.....G..G..A.A.....T..A..CA.G.....	1002
AAV-6A.....	1001
AAV-1	TCGGGTGGCTGGTGGACCGGGGACATCACCTCCGAGAAGCAGTGGATCCAGGAGGACCAGG	1076
AAV-2C.....AA..G..T.....G.....	1062
AAV-6	1061
AAV-1	CCTCGTACATCTCCTCAACGCCGTTCCAACTCGCGTCCCAGATCAAGGCCGCTCTGG	1136
AAV-2A.....T..G..C.....A.....T..CT..	1122
AAV-6	1121
AAV-1	ACAATGCCGGAAAGATCATGGGCTGACCAAATCCGCGCCCGACTACCTGGTAGGCCCG	1196
AAV-2G..A.....T..AGC.....T..A..C.....G.....AGC	1182
AAV-6	1181
AAV-1	CTCCGCCCGCGGACATTAACCAACCGCATCTACCGCATCTGGAGCTGAACGGCTACG	1256
AAV-2	AG..CGTG..A.....TCC..G..T..G..T..TAAA..TT..A..A..G..	1242
AAV-6C.....T.....	1241
AAV-1	AACCTGCCTACGCCGCTCCGCTTCTCGGCTGGGCCAGAAAAGGTTGGAAAGCGCA	1316
AAV-2	.T..CCAA..T..G..CT.....G..A.....AC.....A.....C..A..G.	1302
AAV-6C.....	1301
AAV-1	ACACCATCTGGCTGGCTGGGCCACCACGGCAAGACCAACATCGCGGAAGCCATCG	1376
AAV-2T..A..T..C..G.....G.....A	1362
AAV-6	1361
AAV-1	CCCACGCCGTGCCCTCTACGGCTGCGTCAACTGGACCAATGAGAACTTCCCTCAATG	1436
AAV-2A..T.....G.....A.....	1422
AAV-6	1421
AAV-1	ATTGCGTCGACAAGATGGTGATCTGGTGGGAGGGAGGGCAAGATGACGGCCAAGGTCTGG	1496
AAV-2	.C..T.....G.....C.....	1482
AAV-6	1481
AAV-1	AGTCCGCCAAGGCCATTCTCGGCCGAGCAAGGTGCGCTGGACCAAAAGTGCAGTCGT	1556
AAV-2G.....A.....A..A.....G..A.....C.	1542
AAV-6	1541
AAV-1	CCGCCCCAGATCGACCCCAACCCCGTGTACGTACCTCAACACCAACATGTGCGCCGTGA	1616
AAV-2	.G.....A.....G..T.....	1602
AAV-6T.....	1601

SUBSTITUTE SHEET (RULE 26)

3/13

FIG 1C

FIG 1D

AAV-1 GGACTCGACAAGGGGGAGCCCGTCAACGCGGGACGCAGCGGCCCTCGAGCACGACAAG 2453
 AAV-2A.....G.....A...A....C.....A 2433
 AAV-6T..... 2438

AAV-1 GCCTACGACCAGCAGCTAAAGCGGGTACAATCCGTACCTGCGGTATAACCACGCCGAC 2513
 AAV-2G.....G.CAGC..A.....C.....CAA..C..... 2493
 AAV-6A.AGCG..T.....T.....GCG..T..... 2498

AAV-1 GCGGAGTTTCAGGAGCGTCTGCAAGAAGATACTGTCTTTGGGGCACCTCGGGCGAGCA 2573
 AAV-2 ..G.....C..TA.....A..... 2553
 AAV-6 ..C.....T..GC.....G..... 2558

AAV-1 GTCTTCAGGCCAAGAAGCGGGTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCCTAAG 2633
 AAV-2G..A...A.....T.....G..C.....CCT..T.... 2613
 AAV-6A.....T..T.....T..... 2618

VP2
 AAV-1 ACAGGCTCCTGGAAAGAAACGTCCGGTAGAGCAGTCGCCACAAGAGCCAGACTCCTCCTCG 2693
 AAV-2G.....A..GA..G.....C..T..TGTG..... 2673
 AAV-6T.....G..AC..T.....G..G..ACAA..... 2678

AAV-1 GGCATCGCAAGACAGGCCAGCAGCCCCCTAAAAAGAGACTCAATTGGTCAGACTGGC 2753
 AAV-2 ..A.C...A...G.G.....T..A.G..A..T.G.....A 2733
 AAV-6T..... 2738

AAV-1 GACTCAGAGTCAGTCCCCGATCCACAACCTCTCGGAGAACCTCCAGCAACCCCGCTGCT 2813
 AAV-2 ...G....C....A..T..C..G.....C.G..A.....G....T..G. 2793
 AAV-6 ...T....G....C..C..A..A.....G.A..T.....A.....G.... 2798

VP3
 AAV-1 GTGGGACCTACTACAATGGCTTCAGGCGGTGGCGACCAATGGCAGACAATAACGAAGGC 2873
 AAV-2 C.....A...A..G.....A.....A.....G... 2853
 AAV-6 2858

AAV-1 GCCGACGGAGTGGGTAATGCCTCAGGAAATTGGCATTGCGATTCCACATGGCTGGCGAC 2933
 AAV-2T....C.....A..... 2913
 AAV-6 2918

AAV-1 AGAGTCATCACCAACCGACCCGCACCTGGGCCCTGGCCACCTACAATAACCACTCTAC 2993
 AAV-2A.....C.....C..... 2973
 AAV-6A..A.....T..C..... 2978

AAV-1 AACGAAATCTCCAGTGCTTCACCGGGGGCAGCAACGACAACCACTACTTCGGCTACAGC 3053
 AAV-2 ..A.....T.....CAA..---..A..TCG.....T.....T..... 3030
 AAV-6 3038

AAV-1 ACCCCCTGGGGTATTTGATTTCAACAGATTCCACTGCCACTTTCACCGTGACTGG 3113
 AAV-2T.....C..... 3090
 AAV-6T..C..... 3098

AAV-1 CAGCGACTCATCAACAACAATTGGGATTCCGGCCCAAGAGACTCAACTTCAAACCTTTC 3173
 AAV-2 ..AA.....C.....A.....G.....T 3150
 AAV-6 3158

AAV-1 AACATCCAAGTCAAGGAGGTACGACGAATGATGGCGTCACAAACCATCGCTAATAACCTT 3233
 AAV-2T.....A.....CA.....C..TAGC..G..G..T..C..... 3210
 AAV-6G..... 3218

5/13

FIG 1E

AAV-1	ACCAGCACGGTTCAAGTCTTCTCGGACTCGGAGTACCGAGCTCCGTACGTCCCTCGGCTCT	3293
AAV-2G..G..TA.T.....C.....G	3270
AAV-6T.G.....	3278
AAV-1	GCGCACAGGGCTGCCCTCCCTCGGCGGACGTGTTCATGATTCCGCAATACGGC	3353
AAV-2T..A..A.....G.....A..A.....C.....G.G..A..G..T..A	3330
AAV-6	3338
AAV-1	TACCTGACGCTCAACAATGGCAGCCAAGCGTGGGACGTTCATCCTTTACTGCCTGGAA	3413
AAV-2C..C..G..C..G..T..G..A..A.....C..T..A.....G	3390
AAV-6A.....G..A.....G	3398
AAV-1	TATTTCCCTCTCAGATGCTGAGAACGGCAACAACCTTACCTCAGCTACACCTTGAG	3473
AAV-2	..C..T.....C.T..C..A.....T.....T..C.....G	3450
AAV-6A..G.....T.....C..	3458
AAV-1	GAAGTGCCTTCCACAGCAGCTACGCCACAGCCAGAGCCTGGACCGGCTGATGAATCCT	3533
AAV-2	..C..T.....T.....T.....T..C.....T..C.....G	3510
AAV-6	..C.....T.....C.....G	3498
AAV-1	CTCATCGACCAATACCTGTATTACCTGAACAGAACTCAAAATCAGTCCGGAAGTGCCAA	3593
AAV-2G.....T..G.....AA.C.C..CAAGT....CCA..ACG	3570
AAV-6G.....G.....G	3578
AAV-1	ACAAAGGACTTGCTTTAGCCGTGGCTCCAGCTGGCATGTCAGCTCAGCCCCAAAAC	3653
AAV-2	C..GTCAAGGC..T..A..TCT..AG..CCGGAG..GAG..A..TCGG..AC..T..T..GG..	3630
AAV-6G.....G.....G	3638
AAV-1	TGGCTACCTGGACCCCTGTTATCGGCAGCAGCGCGTTCTAAACAAAAACAGACAACAAAC	3713
AAV-2T.....C..C.....A..A..CA..G..TCTG..G..T.....G	3690
AAV-6C.....T.....T..A.....T..A	3698
AAV-1	AACAGCAATTTCACCTGGACTGGTCTCAAAATATAACCTCAATGGCGTGAATCCATC	3773
AAV-2TG..A..ACT..G.....A..A..C..G..CC.....CA..A..C..TC..G	3750
AAV-6C.....T.....T..A.....T..A	3758
AAV-1	ATCAACCCCTGGACTGCTATGCCCTCACACAAAGACGACGAAGACAAGTTCTTCCATG	3833
AAV-2	G..G..T..G..GC..C..C.....AAGC.....G.....T.....A.....T.....TCA..	3810
AAV-6A.....A.....A	3818
AAV-1	AGCGGTGTCAATTGATTTGGAAAAAGAGAGCGCCGGAGCTCAAAACACTGCATTGGACAAT	3893
AAV-2G..TC..C..C....G..GC..AG..T..A..AGAAA....TGTGAACA..T..A..G	3870
AAV-6G.....G.....G	3878
AAV-1	GTCATGATTACAGACGAAGAGGAATTAAAGCCACTAACCTGTGGCCACCGAAAGATT	3953
AAV-2CGG..A..A..C..T..C.....T..G..GCAG..A..	3930
AAV-6C.....C.....C	3938
AAV-1	GGGACCGTGGCACTCAATTCCAGAGCAGCAGCACAGACCCCTGCAGCGAGATGTGCAT	4013
AAV-2	..TT..T..AT..TAC..CC.....AG..A..G..C..AG..A..T..C.....CA..C	3990
AAV-6T.....C.....C	3998
AAV-1	GCTATGGGAGCATTACCTGGCATGGTGTGGCAAGATAGAGACGTGACCTGCAGGGTCCC	4073
AAV-2	A..ACAA..C..TTC..T..A.....C.....G..C.....T.....T..G..T	4050
AAV-6	T.....C.....A.....C.....A.....T	4058

6/13

FIG 1F

AAV-1 ATTTGGGCCAAAATTCCTCACACAGATGGACACTTCACCCGTCTCCCTTTATGGGCGGC 4133
 AAV-2 ..C.....A..G.....A.....G..C.....T.....C.....C..C.....T..A 4110
 AAV-6G.....C..... 4118

AAV-1 TTTGGACTCAAGAACCCGCCCTCCTCAGATCCTCATCAAAACACGCCCTGTTCTGCGAAT 4193
 AAV-2 ..C.....T..AC....T.....A.....T.....G.....C..G..A..... 4170
 AAV-6T..C..... 4178

AAV-1 CCTCCGGCGGAGTTTCAGCTACAAAGTTGCTTCATTCACTACCCAATACTCCACAGGA 4253
 AAV-2 ..T..A.CACC..CACT..GG.....C.....A..G.....G... 4230
 AAV-6A.....G.....G..T..... 4238

AAV-1 CA-AGT GAGTGTGGAAATTGAATGGGAGCTGCAGAARGAAAACAGCAAGCGCTGGAATCC 4312
 AAV-2 ..CG..C..C.....G..C..G.....G.....A..... 4290
 AAV-6C.....G.....A..... 4297

AAV-1 CGAAGTGCAGTACACATCCAATTATGCCAAATCTGCCAA-CGTTGATTTACTGTGGACA 4371
 AAV-2A.T.....T.....C..CAAC..G....TT..T..G..C.....C.....T. 4350
 AAV-6T.....T..C..... 4356

AAV-1 ACAATGGACTTTATACTGAGCCTGCCATTGGCACCCGTTACCTTACCCGTCCCTGT 4431
 AAV-2 CT.....CG..G...T.A.....A.A.....G..T...AAT.... 4410
 AAV-6C..... 4416

VP1-3 stop PolyA signal
 AAV-1 AATTACGTGTTAACATAAAACCGTTGATTGTTAGTTGAACTTGGTCTCCTGTCC 4491
 AAV-2G.T.....T..A..... 4470
 AAV-6GT.....A.....G 4476

AAV-1 TTCTTATCTTATC-GGTTACCATGGTTAT-AGCTTACACATTA--ACTGCTGGTTGCGC 4547
 AAV-2 ..TC..T.....TA..T.....C..CGTAGA..AGT..GC..TGG..G..G..AA..CATTA 4530
 AAV-6 ..A.....T..C.....A..CA..C-C..G.....A..... 4533

AAV-1 TTCCGCATAAAAGACTTACGTCATCGGttacccttagtgtatggagttggccactccctc 4607
 AAV-2 ACTA..A..gg..a-----g..... 4570
 AAV-6at----- 4572

AAV-1 tctgcgcgcgtcgctcgctcggtggggccggcagagcagagctctgcgtctgcggacctt 4667
 AAV-2 ..c.....ac..a.....gc..c..a..g..gc...a..gc..c..gg... 4630
 AAV-6 ..a.....g..... 4632

AAV-1 tggtccgcaggccccaccgcagcgagcgagcgccagagaggagtgggcaa 4718
 AAV-2 ..cc..g..gc....t..gt.....C... 4681
 AAV-6t..... 4683

FIG 2

SUBSTITUTE SHEET (RULE 26)




FIG. 3A




FIG. 3B

10/13




FIG. 4A

SUBSTITUTE SHEET (RULE 26)

11/13




FIG. 4B

SUBSTITUTE SHEET (RULE 26)

FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D



Group	1	2	3	4	5	6
Vector1-α1AT	AAV2	AAV1	PBS	PBS	AAV2	AAV1
Vector2-EPO	AAV2	AAV1	AAV2	AAV1	AAV1	AAV2

13/13

FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D



Group	1	2	3	4	5	6
Vector1 - $\alpha 1AT$	AAV2	AAV1	PBS	PBS	AAV2	AAV1
Vector2 - EPO	AAV2	AAV1	AAV2	AAV1	AAV1	AAV2

SEQUENCE LISTING

<110> Wilson, James M.
Xiao, Weidong
The Trustees of the University of Pennsylvania

<120> Adeno-Associated Virus Serotype I Nucleic Acid
Sequences, Vectors and Host Cells Containing Same

<130> GNVPN.031PCT

<140>

<141>

<150> 60/107,114
<151> 1998-11-05

<160> 20

<170> PatentIn Ver. 2.0

<210> 1
<211> 4718
<212> DNA
<213> AAV-1

<220>

<221> CDS
<222> (335)..(2206)

<220>

<221> CDS
<222> (2223)..(4430)

<400> 1
ttgccccactc cctctctgctcg cgctcgctcg ctcgggtgggg cctgcggacc aaagggtccgc 60
agacggcaga gctctgctct gcccggccca ccgagcgagc gagcgcgcag agagggagtg 120
ggcaactcca tcacttagggg taatcgcgaa ggcgcctccca cgctgcccgcg tcagcgctga 180
cgtaaattac gtcatagggg agtgggtcctg tattagctgt cacgtgagtg cttttgcgac 240
attttgcac accacgtggc catttagggt atatatggcc gagtgagcga gcaggatctc 300
cattttgacc gcgaaatttg aacgagcagc agcc atg ccg ggc ttc tac gag atc 355
Met Pro Gly Phe Tyr Glu Ile
1 5

gtg atc aag gtg ccg agc gac ctg gac gag cac ctg ccg ggc att tct	403		
Val Ile Lys Val Pro Ser Asp Leu Asp Glu His Leu Pro Gly Ile Ser			
10	15	20	
gac tcg ttt gtg agc tgg gtg gcc gag aag gaa tgg gag ctg ccc ccg	451		
Asp Ser Phe Val Ser Trp Val Ala Glu Lys Glu Trp Glu Leu Pro Pro			
25	30	35	
gat tct gac atg gat ctg aat ctg att gag cag gca ccc ctg acc gtg	499		
Asp Ser Asp Met Asp Leu Asn Leu Ile Glu Gln Ala Pro Leu Thr Val			
40	45	50	55
gcc gag aag ctg cag cgc gac ttc ctg gtc caa tgg cgc cgc gtg agt	547		
Ala Glu Lys Leu Gln Arg Asp Phe Leu Val Gln Trp Arg Arg Val Ser			
60	65	70	
aag gcc ccg gag gcc ctc ttc ttt gtt cag ttc gag aag ggc gag tcc	595		
Lys Ala Pro Glu Ala Leu Phe Phe Val Gln Phe Glu Lys Gly Glu Ser			
75	80	85	
tac ttc cac ctc cat att ctg gtg gag acc acg ggg gtc aaa tcc atg	643		
Tyr Phe His Leu His Ile Leu Val Glu Thr Thr Gly Val Lys Ser Met			
90	95	100	
gtg ctg ggc cgc ttc ctg agt cag att agg gac aag ctg gtg cag acc	691		
Val Leu Gly Arg Phe Leu Ser Gln Ile Arg Asp Lys Leu Val Gln Thr			
105	110	115	
atc tac cgc ggg atc gag ccg acc ctg ccc aac tgg ttc gcg gtg acc	739		
Ile Tyr Arg Gly Ile Glu Pro Thr Leu Pro Asn Trp Phe Ala Val Thr			
120	125	130	135
aag acg cgt aat ggc gcc gga ggg ggg aac aag gtg gtg gac gag tgc	787		
Lys Thr Arg Asn Gly Ala Gly Gly Asn Lys Val Val Asp Glu Cys			
140	145	150	
tac atc ccc aac tac ctc ctg ccc aag act cag ccc gag ctg cag tgg	835		
Tyr Ile Pro Asn Tyr Leu Leu Pro Lys Thr Gln Pro Glu Leu Gln Trp			
155	160	165	
gcg tgg act aac atg gag gag tat ata agc gcc tgt ttg aac ctg gcc	883		
Ala Trp Thr Asn Met Glu Glu Tyr Ile Ser Ala Cys Leu Asn Leu Ala			
170	175	180	
gag cgc aaa cgg ctc gtg gcg cag cac ctg acc cac gtc agc cag acc	931		
Glu Arg Lys Arg Leu Val Ala Gln His Leu Thr His Val Ser Gln Thr			
185	190	195	

cag gag cag aac aag gag aat ctg aac ccc aat tct gac gcg cct gtc	979		
Gln Glu Gln Asn Lys Glu Asn Leu Asn Pro Asn Ser Asp Ala Pro Val			
200	205	210	215
atc cgg tca aaa acc tcc gcg cgc tac atg gag ctg gtc ggg tgg ctg	1027		
Ile Arg Ser Lys Thr Ser Ala Arg Tyr Met Glu Leu Val Gly Trp Leu			
220	225	230	
gtg gac cgg ggc atc acc tcc gag aag cag tgg atc cag gag gac cag	1075		
Val Asp Arg Gly Ile Thr Ser Glu Lys Gln Trp Ile Gln Glu Asp Gln			
235	240	245	
gcc tcg tac atc tcc ttc aac gcc gct tcc aac tcg cgg tcc cag atc	1123		
Ala Ser Tyr Ile Ser Phe Asn Ala Ala Ser Asn Ser Arg Ser Gln Ile			
250	255	260	
aag gcc gct ctg gac aat gcc ggc aag atc atg gcg ctg acc aaa tcc	1171		
Lys Ala Ala Leu Asp Asn Ala Gly Lys Ile Met Ala Leu Thr Lys Ser			
265	270	275	
gcg ccc gac tac ctg gta ggc ccc gct ccg ccc gcg gac att aaa acc	1219		
Ala Pro Asp Tyr Leu Val Gly Pro Ala Pro Pro Ala Asp Ile Lys Thr			
280	285	290	295
aac cgc atc tac cgc atc ctg gag ctg aac ggc tac gaa cct gcc tac	1267		
Asn Arg Ile Tyr Arg Ile Leu Glu Leu Asn Gly Tyr Glu Pro Ala Tyr			
300	305	310	
gcc ggc tcc gtc ttt ctc ggc tgg gcc cag aaa agg ttc ggg aag cgc	1315		
Ala Gly Ser Val Phe Leu Gly Trp Ala Gln Lys Arg Phe Gly Lys Arg			
315	320	325	
aac acc atc tgg ctg ttt ggg ccg gcc acc acg ggc aag acc aac atc	1363		
Asn Thr Ile Trp Leu Phe Gly Pro Ala Thr Thr Gly Lys Thr Asn Ile			
330	335	340	
gcg gaa gcc atc gcc cac gcc gtg ccc ttc tac ggc tgc gtc aac tgg	1411		
Ala Glu Ala Ile Ala His Ala Val Pro Phe Tyr Gly Cys Val Asn Trp			
345	350	355	
acc aat gag aac ttt ccc ttc aat gat tgc gtc gac aag atg gtg atc	1459		
Thr Asn Glu Asn Phe Pro Phe Asn Asp Cys Val Asp Lys Met Val Ile			
360	365	370	375
tgg tgg gag gag ggc aag atg acg gcc aag gtc gtg gag tcc gcc aag	1507		
Trp Trp Glu Glu Gly Lys Met Thr Ala Lys Val Val Glu Ser Ala Lys			
380	385	390	

gcc att ctc ggc ggc agc aag gtg cgc gtg gac caa aag tgc aag tcg	1555
Ala Ile Leu Gly Gly Ser Lys Val Arg Val Asp Gln Lys Cys Lys Ser	
395	400
405	
tcc gcc cag atc gac ccc acc ccc gtg atc gtc acc tcc aac acc aac	1603
Ser Ala Gln Ile Asp Pro Thr Pro Val Ile Val Thr Ser Asn Thr Asn	
410	415
420	
atg tgc gcc gtg att gac ggg aac agc acc acc ttc gag cac cag cag	1651
Met Cys Ala Val Ile Asp Gly Asn Ser Thr Thr Phe Glu His Gln Gln	
425	430
435	
ccg ttg cag gac cgg atg ttc aaa ttt gaa ctc acc cgc cgt ctg gag	1699
Pro Leu Gln Asp Arg Met Phe Lys Phe Glu Leu Thr Arg Arg Leu Glu	
440	445
450	455
cat gac ttt ggc aag gtg aca aag cag gaa gtc aaa gag ttc ttc cgc	1747
His Asp Phe Gly Lys Val Thr Lys Gln Glu Val Lys Glu Phe Phe Arg	
460	465
470	
tgg gcg cag gat cac gtg acc gag gtg gcg cat gag ttc tac gtc aga	1795
Trp Ala Gln Asp His Val Thr Glu Val Ala His Glu Phe Tyr Val Arg	
475	480
485	
aag ggt gga gcc aac aaa aga ccc gcc ccc gat gac gcg gat aaa agc	1843
Lys Gly Ala Asn Lys Arg Pro Ala Pro Asp Asp Ala Asp Lys Ser	
490	495
500	
gag ccc aag cgg gcc tgc ccc tca gtc gcg gat cca tcg acg tca gac	1891
Glu Pro Lys Arg Ala Cys Pro Ser Val Ala Asp Pro Ser Thr Ser Asp	
505	510
515	
gcg gaa gga gct ccg gtg gac ttt gcc gac agg tac caa aac aaa tgt	1939
Ala Glu Gly Ala Pro Val Asp Phe Ala Asp Arg Tyr Gln Asn Lys Cys	
520	525
530	535
tct cgt cac gcg ggc atg ctt cag atg ctg ttt ccc tgc aag aca tgc	1987
Ser Arg His Ala Gly Met Leu Gln Met Leu Phe Pro Cys Lys Thr Cys	
540	545
550	
gag aga atg aat cag aat ttc aac att tgc ttc acg cac ggg acg aga	2035
Glu Arg Met Asn Gln Asn Phe Asn Ile Cys Phe Thr His Gly Thr Arg	
555	560
565	
gac tgt tca gag tgc ttc ccc ggc gtg tca gaa tct caa ccg gtc gtc	2083
Asp Cys Ser Glu Cys Phe Pro Gly Val Ser Glu Ser Gln Pro Val Val	
570	575
580	

aga aag agg acg tat cgg aaa ctc tgt gcc att cat cat ctg ctg ggg 2131
 Arg Lys Arg Thr Tyr Arg Lys Leu Cys Ala Ile His His Leu Leu Gly
 585 590 595

cgg gct ccc gag att gct tgc tcg gcc tgc gat ctg gtc aac gtg gac 2179
 Arg Ala Pro Glu Ile Ala Cys Ser Ala Cys Asp Leu Val Asn Val Asp
 600 605 610 615

ctg gat gac tgt gtt tct gag caa taa atgacttaaa ccaggt atg gct gcc 2231
 Leu Asp Asp Cys Val Ser Glu Gln Met Ala Ala
 620 625

gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct gag ggc att 2279
 Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser Glu Gly Ile
 630 635 640

cgc gag tgg tgg gac ttg aaa cct gga gcc ccg aag ccc aaa gcc aac 2327
 Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro Lys Ala Asn
 645 650 655

cag caa aag cag gac gac ggc cgg ggt ctg gtg ctt cct ggc tac aag 2375
 Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro Gly Tyr Lys
 660 665 670 675

tac ctc gga ccc ttc aac gga ctc gac aag ggg gag ccc gtc aac gcg 2423
 Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro Val Asn Ala
 680 685 690

gcg gac gca gcg gcc ctc gag cac gac aag gcc tac gac cag cag ctc 2471
 Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln Gln Leu
 695 700 705

aaa gcg ggt gac aat ccg tac ctg cgg tat aac cac gcc gac gcc gag 2519
 Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala Asp Ala Glu
 710 715 720

ttt cag gag cgt ctg caa gaa gat acg tct ttt ggg ggc aac ctc ggg 2567
 Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly Asn Leu Gly
 725 730 735

cga gca gtc ttc cag gcc aag aag cgg gtt ctc gaa cct ctc ggt ctg 2615
 Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu Gly Leu
 740 745 750 755

gtt gag gaa ggc gct aag acg gct cct gga aag aaa cgt ccg gta gag 2663
 Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro Val Glu
 760 765 770

cag tcg cca caa gag cca gac tcc tcc tcg ggc atc ggc aag aca ggc	2711
Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly	
775 780 785	
cag cag ccc gct aaa aag aga ctc aat ttt ggt cag act ggc gac tca	2759
Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser	
790 795 800	
gag tca gtc ccc gat cca caa cct ctc gga gaa cct cca gca acc ccc	2807
Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro	
805 810 815	
gct gct gtg gga cct act aca atg gct tca ggc ggt ggc gca cca atg	2855
Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Ala Pro Met	
820 825 830 835	
gca gac aat aac gaa ggc gac gga gtg ggt aat gcc tca gga aat	2903
Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn	
840 845 850	
tgg cat tgc gat tcc aca tgg ctg ggc gac aga gtc atc acc acc agc	2951
Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser	
855 860 865	
acc cgc acc tgg gcc ttg ccc acc tac aat aac cac ctc tac aag caa	2999
Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln	
870 875 880	
atc tcc agt gct tca acg ggg gcc agc aac gac aac cac tac ttc ggc	3047
Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His Tyr Phe Gly	
885 890 895	
tac agc acc ccc tgg ggg tat ttt gat ttc aac aga ttc cac tgc cac	3095
Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His	
900 905 910 915	
ttt tca cca cgt gac tgg cag cga ctc atc aac aac aat tgg gga ttc	3143
Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe	
920 925 930	
cgg ccc aag aga ctc aac ttc aaa ctc ttc aac atc caa gtc aag gag	3191
Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu	
935 940 945	
gtc acg acg aat gat ggc gtc aca acc atc gct aat aac ctt acc agc	3239
Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser	
950 955 960	

acg gtt caa gtc ttc tcg gac tcg gag tac cag ctt ccg tac gtc ctc	3287
Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu	
965 970 975	
ggc tct gcg cac caa ggc tgc ctc cct ccg ttc ccg gcg gac gtg ttc	3335
Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe	
980 985 990 995	
atg att ccg caa tac ggc tac ctg acg ctc aac aat ggc agc caa gcc	3383
Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala	
1000 1005 1010	
gtg gga cgt tca tcc ttt tac tgc ctg gaa tat ttc cct tct cag atg	3431
Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met	
1015 1020 1025	
ctg aga acg ggc aac aac ttt acc ttc agc tac acc ttt gag gaa gtg	3479
Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu Glu Val	
1030 1035 1040	
cct ttc cac agc agc tac gcg cac agc cag agc ctg gac cgg ctg atg	3527
Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met	
1045 1050 1055	
aat cct ctc atc gac caa tac ctg tat tac ctg aac aga act caa aat	3575
Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln Asn	
1060 1065 1070 1075	
cag tcc gga agt gcc caa aac aag gac ttg ctg ttt agc cgt ggg tct	3623
Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser	
1080 1085 1090	
cca gct ggc atg tct gtt cag ccc aaa aac tgg cta cct gga ccc tgt	3671
Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys	
1095 1100 1105	
tat cgg cag cag cgc gtt tct aaa aca aaa aca gac aac aac agc	3719
Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser	
1110 1115 1120	
aat ttt acc tgg act ggt gct tca aaa tat aac ctc aat ggg cgt gaa	3767
Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu	
1125 1130 1135	
tcc atc atc aac cct ggc act gct atg gcc tca cac aaa gac gac gaa	3815
Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys Asp Asp Glu	
1140 1145 1150 1155	

gac aag ttc ttt ccc atg agc ggt gtc atg att ttt gga aaa gag agc	3863		
Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly Lys Glu Ser			
1160	1165	1170	
gcc gga gct tca aac act gca ttg gac aat gtc atg att aca gac gaa	3911		
Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile Thr Asp Glu			
1175	1180	1185	
gag gaa att aaa gcc act aac cct gtg gcc acc gaa aga ttt ggg acc	3959		
Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg Phe Gly Thr			
1190	1195	1200	
gtg gca gtc aat ttc cag agc agc aca gac cct gcg acc gga gat	4007		
Val Ala Val Asn Phe Gln Ser Ser Thr Asp Pro Ala Thr Gly Asp			
1205	1210	1215	
gtg cat gct atg gga gca tta cct ggc atg gtg tgg caa gat aga gac	4055		
Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln Asp Arg Asp			
1220	1225	1230	1235
gtg tac ctg cag ggt ccc att tgg gcc aaa att cct cac aca gat gga	4103		
Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly			
1240	1245	1250	
cac ttt cac ccg tct cct ctt atg ggc ggc ttt gga ctc aag aac ccg	4151		
His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys Asn Pro			
1255	1260	1265	
cct cct cag atc ctc atc aaa aac acg cct gtt cct gcg aat cct ccg	4199		
Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro			
1270	1275	1280	
gcg gag ttt tca gct aca aag ttt gct tca ttc atc acc caa tac tcc	4247		
Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser			
1285	1290	1295	
aca gga caa gtg agt gtg gaa att gaa tgg gag ctg cag aaa gaa aac	4295		
Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn			
1300	1305	1310	1315
agc aag cgc tgg aat ccc gaa gtg cag tac aca tcc aat tat gca aaa	4343		
Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys			
1320	1325	1330	
tct gcc aac gtt gat ttt act gtg gac aac aat gga ctt tat act gag	4391		
Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu			
1335	1340	1345	

cct cgc ccc att ggc acc cgt tac ctt acc cgt ccc ctg taattacgtg 4440
 Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
 1350 1355 1360

 ttaatcaata aaccgggttga ttcgtttcag ttgaactttg gtctcctgtc cttcttatct 4500

 tatcggttac catggttata gcttacacat taactgcttg gttgcgcttc gcgataaaag 4560

 acttacgtca tcgggttacc cctagtgtat gagttgccc a cccctctc gcgcgcgc 4620

 tcgcctggtg gggcctgcgg accaaaggc cgcagacggc agagctctgc tctgcccggcc 4680

 ccaccgagcg agcgagcgcg cagagaggga gtgggcaa 4718

<210> 2
 <211> 623
 <212> PRT
 <213> AAV-1

<400> 2
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
 1 5 10 15

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu
 20 25 30

Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
 35 40 45

Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
 50 55 60

Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
 65 70 75 80

Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
 85 90 95

Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
 100 105 110

Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
 115 120 125

Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
 130 135 140

Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
 145 150 155 160
 Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
 165 170 175
 Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
 180 185 190
 Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
 195 200 205
 Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
 210 215 220
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
 225 230 235 240
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
 245 250 255
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
 260 265 270
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
 275 280 285
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
 290 295 300
 Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
 305 310 315 320
 Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
 325 330 335
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
 340 345 350
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
 355 360 365
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
 370 375 380
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
 385 390 395 400

Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
405 410 415

Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
420 425 430

Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
435 440 445

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln
450 455 460

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val
465 470 475 480

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
485 490 495

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val
500 505 510

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
515 520 525

Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met
530 535 540

Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile
545 550 555 560

Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val
565 570 575

Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys
580 585 590

Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala
595 600 605

Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln
610 615 620

<210> 3
<211> 736
<212> PRT
<213> AAV-1

<400> 3
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu

245	250	255
Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His		
260	265	270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe		
275	280	285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn		
290	295	300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln		
305	310	315
320		
Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn		
325	330	335
Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro		
340	345	350
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala		
355	360	365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly		
370	375	380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro		
385	390	395
400		
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe		
405	410	415
Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp		
420	425	430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg		
435	440	445
Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser		
450	455	460
Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro		
465	470	475
480		
Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn		
485	490	495
Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn		

500 505 510

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
530 535 540

Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
545 550 555 560

Thr Asp Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
565 570 575

Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
580 585 590

Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
690 695 700

Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
705 710 715 720

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725 730 735

<210> 4
<211> 1872
<212> DNA

<213> AAV-1

<220>

<221> CDS

<222> (1)..(1869)

<400> 4

atg	ccg	ggc	ttc	tac	gag	atc	gtg	atc	aag	gtg	ccg	agc	gac	ctg	gac	48
Met	Pro	Gly	Phe	Tyr	Glu	Ile	Val	Ile	Lys	Val	Pro	Ser	Asp	Leu	Asp	
1															15	

gag	cac	ctg	ccg	ggc	att	tct	gac	tcg	ttt	gtg	agc	tgg	gtg	gcc	gag	96
Glu	His	Leu	Pro	Gly	Ile	Ser	Asp	Ser	Phe	Val	Ser	Trp	Val	Ala	Glu	
20															30	

aag	gaa	tgg	gag	ctg	ccc	ccg	gat	tct	gac	atg	gat	ctg	aat	ctg	att	144
Lys	Glu	Trp	Glu	Leu	Pro	Pro	Asp	Ser	Asp	Met	Asp	Leu	Asn	Leu	Ile	
35															45	

gag	cag	gca	ccc	ctg	acc	gtg	gcc	gag	aag	ctg	cag	ccg	gac	ttc	ctg	192
Glu	Gln	Ala	Pro	Leu	Thr	Val	Ala	Glu	Lys	Leu	Gln	Arg	Asp	Phe	Leu	
50															60	

gtc	caa	tgg	ccg	ccg	gtg	agt	aag	gcc	ccg	gag	gcc	ctc	ttc	ttt	gtt	240
Val	Gln	Trp	Arg	Arg	Val	Ser	Lys	Ala	Pro	Glu	Ala	Leu	Phe	Phe	Val	
65															80	

cag	ttc	gag	aag	ggc	gag	tcc	tac	tcc	cac	ctc	cat	att	ctg	gtg	gag	288
Gln	Phe	Glu	Lys	Gly	Glu	Ser	Tyr	Phe	His	Leu	His	Ile	Leu	Val	Glu	
85															95	

acc	acg	ggg	gtc	aaa	tcc	atg	gtg	ctg	ggc	ccg	ccg	ttc	ctg	agt	cag	att	336
Thr	Thr	Gly	Val	Lys	Ser	Met	Val	Gly	Arg	Phe	Leu	Ser	Gln	Ile			
100															110		

agg	gac	aag	ctg	gtg	cag	acc	atc	tac	ccg	ggg	atc	gag	ccg	acc	ctg	384
Arg	Asp	Lys	Leu	Val	Gln	Thr	Ile	Tyr	Arg	Gly	Ile	Glu	Pro	Thr	Leu	
115															125	

ccc	aac	tgg	ttc	gcg	gtg	acc	aag	acg	cgt	aat	ggc	gcc	gga	ggg	ggg	432
Pro	Asn	Trp	Phe	Ala	Val	Thr	Lys	Thr	Arg	Asn	Gly	Ala	Gly	Gly	Gly	
130															140	

aac	aag	gtg	gtg	gac	gag	tgc	tac	atc	ccc	aac	tac	ctc	ctg	ccc	aag	480
Asn	Lys	Val	Val	Asp	Glu	Cys	Tyr	Ile	Pro	Asn	Tyr	Leu	Leu	Pro	Lys	
145															160	

act	cag	ccc	gag	ctg	cag	tgg	ggc	tgg	act	aac	atg	gag	gag	tat	ata	528
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile		
165	170	175
agc gcc tgt ttg aac ctg gcc gag cgc aaa cgg ctc gtg gcg cag cac	576	
Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His		
180	185	190
ctg acc cac gtc agc cag acc cag gag cag aac aag gag aat ctg aac	624	
Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn		
195	200	205
ccc aat tct gac gcg cct gtc atc cgg tca aaa acc tcc gcg cgc tac	672	
Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr		
210	215	220
atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag	720	
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys		
225	230	235
240		
cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct	768	
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala		
245	250	255
tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag	816	
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys		
260	265	270
atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct	864	
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala		
275	280	285
ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg	912	
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu		
290	295	300
aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc	960	
Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala		
305	310	315
320		
cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc	1008	
Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala		
325	330	335
acc acg ggc aag acc aac atc gcg gaa gcc atc gcc cac gcc gtg ccc	1056	
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro		
340	345	350
ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat	1104	

Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp	
355																
																365
tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc 1152																
cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala																
370																380
aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc acg aag gtg cgc 1200																
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg																
385																400
390																
395																
400																
gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg 1248																
Val Asp Gln Lys Cys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val																
405																415
410																
415																
atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac acg 1296																
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser																
420																430
425																
430																
acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt 1344																
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe																
435																445
440																
445																
gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag 1392																
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln																
450																460
455																
460																
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg 1440																
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val																
465																480
470																
475																
480																
gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 1488																
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala																
485																495
490																
495																
ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 1536																
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val																
500																510
505																
510																
gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 1584																
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala																
515																525
520																
525																
gac agg tac caa aac aaa tgt tct cgt cac gcg ggc atg ctt cag atg 1632																
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met																
530																540
535																
540																
ctg ttt ccc tgc aag aca tgc gag aca atg aat cag aat ttc aac att 1680																

Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile
 545 550 555 560
 tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg 1728
 Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val
 565 570 575
 tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt 1776
 Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys
 580 585 590
 gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tcg gcc 1824
 Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala
 595 600 605
 tgc gat ctg gtc aac gtg gac ctg gat gac tgt gtt tct gag caa taa 1872
 Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln
 610 615 620

 <210> 5
 <211> 623
 <212> PRT
 <213> AAV-1

 <400> 5
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
 1 5 10 15
 Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu
 20 25 30
 Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
 35 40 45
 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
 50 55 60
 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
 65 70 75 80
 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
 85 90 95
 Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
 100 105 110
 Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu

115 120 125

Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
130 135 140

Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
145 150 155 160

Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
165 170 175

Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
180 185 190

Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
195 200 205

Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
210 215 220

Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
225 230 235 240

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
245 250 255

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
260 265 270

Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
275 280 285

Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
290 295 300

Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
305 310 315 320

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
325 330 335

Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
340 345 350

Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
355 360 365

Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala

370	375	380
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg		
385	390	395
400		
Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val		
405	410	415
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser		
420	425	430
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe		
435	440	445
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln		
450	455	460
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val		
465	470	475
480		
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala		
485	490	495
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val		
500	505	510
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala		
515	520	525
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met		
530	535	540
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile		
545	550	555
560		
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val		
565	570	575
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys		
580	585	590
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala		
595	600	605
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln		
610	615	620

<210> 6
 <211> 1641
 <212> DNA
 <213> AAV-1

<220>
 <221> CDS
 <222> (1)..(1638)

<400> 6
 atg ccg ggc ttc tac gag atc gtg atc aag gtg ccg agc gac ctg gac 48
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
 1 5 10 15
 gag cac ctg ccg ggc att tct gac tcc ttt gtg agc tgg gtg gcc gag 96
 Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu
 20 25 30
 aag gaa tgg gag ctg ccc ccg gat tct gac atg gat ctg aat ctg att 144
 Lys Glu Trp Glu Ile Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
 35 40 45
 gag cag gca ccc ctg acc gtg gcc gag aag ctg cag cgc gac ttc ctg 192
 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
 50 55 60
 gtc caa tgg cgc cgc gtg agt aag gcc ccg gag gcc ctc ttc ttt gtt 240
 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
 65 70 75 80
 cag ttc gag aag ggc gag tcc tac ttc cac ctc cat att ctg gtg gag 288
 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
 85 90 95
 acc acg ggg gtc aaa tcc atg gtg ctg ggc cgc ttc ctg agt cag att 336
 Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
 100 105 110
 agg gac aag ctg gtg cag acc atc tac cgc ggg atc gag ccg acc ctg 384
 Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
 115 120 125
 ccc aac tgg ttc gcg gtg acc aag acg cgt aat ggc gcc gga ggg ggg 432
 Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
 130 135 140
 aac aag gtg gtg gac gag tgc tac atc ccc aac tac ctc ctg ccc aag 480
 Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys

145	150	155	160	
act cag ccc gag ctg cag tgg gcg tgg act aac atg gag gag tat ata				528
Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile				
165	170	175		
agc gcc tgt ttg aac ctg gcc gag cgc aaa cgg ctc gtg gcg cag cac				576
Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His				
180	185	190		
ctg acc cac gtc agc cag acc cag gag cag aac aag gag aat ctg aac				624
Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn				
195	200	205		
ccc aat tct gac gcg cct gtc atc cgg tca aaa acc tcc gcg cgc tac				672
Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr				
210	215	220		
atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag				720
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys				
225	230	235	240	
cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct				768
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala				
245	250	255		
tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag				816
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys				
260	265	270		
atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct				864
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala				
275	280	285		
ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg				912
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu				
290	295	300		
aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc				960
Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala				
305	310	315	320	
cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc				1008
Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala				
325	330	335		
acc acg ggc aag acc aac atc gcg gaa gcc atc gcc cac gcc gtg ccc				1056
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro				

340	345	350	
ttc tac ggc tgc aac tgg acc aat gag aac ttt ccc ttc aat gat Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp 355	360	365	1104
tgc gtc gac aag atg' gtc atc tgg tgg gag gag ggc aag atg acg gcc Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala 370	375	380	1152
aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg 385	390	395	1200
gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg Val Asp Gln Lys Cys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val 405	410	415	1248
atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser 420	425	430	1296
acc acc ttc gag cac cag cag ccg ttg cag gac ccg atg ttc aaa ttt Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe 435	440	445	1344
gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln 450	455	460	1392
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val 465	470	475	1440
gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc Ala His Glu Phe Tyr Val Arg Lys Gly Ala Asn Lys Arg Pro Ala 485	490	495	1488
ccc gat gac gcg gat aaa agc gag ccc aag ccg gcc tgc ccc tca gtc Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val 500	505	510	1536
gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala 515	520	525	1584
gac agg tat ggc tgc cga tgg tta tct tcc aga ttg gct cga gga caa Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln			1632

530

535

540

cct ctc tga
Pro Leu
545

1641

<210> 7
<211> 546
<212> PRT
<213> AAV-1<400> 7
Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
1 5 10 15Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu
20 25 30Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
35 40 45Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
50 55 60Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
65 70 75 80Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
85 90 95Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
100 105 110Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
115 120 125Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly
130 135 140Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
145 150 155 160Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
165 170 175Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
180 185 190

Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
195 200 205

Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
210 215 220

Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
225 230 235 240

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
245 250 255

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
260 265 270

Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
275 280 285

Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
290 295 300

Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
305 310 315 320

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
325 330 335

Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
340 345 350

Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
355 360 365

Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
370 375 380

Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
385 390 395 400

Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
405 410 415

Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
420 425 430

Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
435 440 445

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln
450 455 460

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val
465 470 475 480

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
485 490 495

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val
500 505 510

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
515 520 525

Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln
530 535 540

Pro Leu
545

<210> 8
<211> 1200
<212> DNA
<213> AAV-1

<220>
<221> CDS
<222> (1)..(1197)

<400> 8
atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag 48
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
1 5 10 15

cag tgg atc cag gag gac cag gcc tcc tac atc tcc ttc aac gcc gct 96
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
20 25 30

tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag 144
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
35 40 45

atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct 192
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
50 55 60

ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg	240
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu	
65 70 75 80	
aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc	288
Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala	
85 90 95	
cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc	336
Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala	
100 105 110	
acc acg ggc aag acc aac atc cgc gaa gcc atc gcc cac gcc gtg ccc	384
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro	
115 120 125	
ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat	432
Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp	
130 135 140	
tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc	480
Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala	
145 150 155 160	
aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc	528
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg	
165 170 175	
gtg gac caa aag tgc aag tgc tcc gcc cag atc gac ccc acc ccc gtg	576
Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val	
180 185 190	
atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc	624
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser	
195 200 205	
acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt	672
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe	
210 215 220	
gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag	720
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln	
225 230 235 240	
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg	768
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val	
245 250 255	

gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 816
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
 260 265 270

ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 864
 Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val
 275 280 285

gcg gat cca tcg acg tca gac gcg gaa gga gct ccc gtg gac ttt gcc 912
 Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
 290 295 300

gac agg tac caa aac aaa tgt tct cgt cac gcg ggc atg ctt cag atg 960
 Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met
 305 310 315 320

ctg ttt ccc tgc aag aca tgc gag aga atg aat cag aat ttc aac att 1008
 Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile
 325 330 335

tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg 1056
 Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val
 340 345 350

tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt 1104
 Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys
 355 360 365

gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tgc gcc 1152
 Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala
 370 375 380

tgc gat ctg gtc aac gtg gac ctg gat gac tgt gtt tct gag caa taa 1200
 Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln
 385 390 395

<210> 9
 <211> 399
 <212> PRT
 <213> AAV-1

<400> 9
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
 1 5 10 15

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala

20 25 30

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
35 40 45

Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
50 55 60

Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
65 70 75 80

Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
85 90 95

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
100 105 110

Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
115 120 125

Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
130 135 140

Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
145 150 155 160

Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
165 170 175

Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
180 185 190

Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
195 200 205

Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
210 215 220

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln
225 230 235 240

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val
245 250 255

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
260 265 270

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val

275 280 285

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
290 295 300Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met
305 310 315 320Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile
325 330 335Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val
340 345 350Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys
355 360 365Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala
370 375 380Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln
385 390 395<210> 10
<211> 969
<212> DNA
<213> AAV-1<220>
<221> CDS
<222> (1)..(966)<220>
<221> misc_feature
<222> (943)..(944)
<223> minor splice site<400> 10
atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag 48
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
1 5 10 15cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct 96
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
20 25 30

tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag 144

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
 35 40 45
 atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct 192
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
 50 55 60
 ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg 240
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
 65 70 75 80
 aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc 288
 Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
 85 90 95
 cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc 336
 Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
 100 105 110
 acc acg ggc aag acc aac atc gcg gaa gcc atc gcc cac gcc gtg ccc 384
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
 115 120 125
 ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat 432
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
 130 135 140
 tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc 480
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
 145 150 155 160
 aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc 528
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
 165 170 175
 gtg gac caa aag tgc aag tgc tcc gcc cag atc gac ccc acc ccc gtg 576
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
 180 185 190
 atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc 624
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
 195 200 205
 acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt 672
 Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
 210 215 220
 gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag 720

Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
225					230					235					240
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg 768															
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val															
245					250					255					
gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 816															
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala															
260					265					270					
ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 864															
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val															
275					280					285					
gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 912															
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala															
290					295					300					
gac agg tat ggc tgc cga tgg tta tct tcc aga ttg gct cga gga caa 960															
Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln															
305					310					315					320
cct ctc tga 969															
Pro Leu															
<210> 11															
<211> 322															
<212> PRT															
<213> AAV-1															
<400> 11															
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys															
1					5					10					15
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala															
20					25					30					
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys															
35					40					45					
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala															
50					55					60					
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu															
65					70					75					80

Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
85 90 95

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
100 105 110

Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
115 120 125

Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
130 135 140

Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
145 150 155 160

Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
165 170 175

Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
180 185 190

Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
195 200 205

Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
210 215 220

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln
225 230 235 240

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val
245 250 255

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
260 265 270

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val
275 280 285

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
290 295 300

Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln
305 310 315 320

Pro Leu

```

<210> 12
<211> 2211
<212> DNA
<213> AAV-1

<220>
<221> CDS
<222> (1)..(2208)

<400> 12
atg gct gcc gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct 48
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

gag ggc att cgc gag tgg tgg gac ttg aaa cct gga gcc ccg aag ccc 96
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

aaa gcc aac cag caa aag cag gac ggc cgg ggt ctg gtg ctt cct 144
Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

ggc tac aag tac ctc gga ccc ttc aac gga ctc gac aag ggg gag ccc 192
Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

gtc aac gcg gcg gac gca gcg gcc ctc gag cac gac aag gcc tac gac 240
Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

cag cag ctc aaa gcg ggt gac aat ccg tac ctg cgg tat aac cac gcc 288
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

gac gcc gag ttt cag gag cgt ctg caa gaa gat acg tct ttt ggg ggc 336
Asp Ala Glu Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

aac ctc ggg cga gca gtc ttc cag gcc aag aag cgg gtt ctc gaa cct 384
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

ctc ggt ctg gtt gag gaa ggc gct aag acg gct cct gga aag aaa cgt 432
Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

ccg gta gag cag tcg cca caa gag cca gac tcc tcc tcg ggc atc ggc 480

```

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 145 150 155 160
 aag aca ggc cag cag ccc gct aaa aag aga ctc aat ttt ggt cag act 528
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 ggc gac tca gag tca gtc ccc gat cca caa cct ctc gga gaa cct cca 576
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 gca acc ccc gct gct gtg gga cct act aca atg gct tca ggc ggt ggc 624
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 gca cca atg gca gac aat aac gaa ggc gac gga gtg ggt aat gcc 672
 Ala Pro Met Ala Asp Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 tca gga aat tgg cat tgc gat tcc aca tgg ctg ggc gac aga gtc atc 720
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 acc acc agc acc cgc acc tgg gcc ttg ccc acc tac aat aac cac ctc 768
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 tac aag caa atc tcc agt gct tca acg ggg gcc agc aac gac aac cac 816
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 tac ttc ggc tac agc acc ccc tgg ggg tat ttt gat ttc aac aga ttc 864
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
 275 280 285
 cac tgc cac ttt tca cca cgt gac tgg cag cga ctc atc aac aac aat 912
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
 290 295 300
 tgg gga ttc cgg ccc aag aga ctc aac ttc aaa ctc ttc aac atc caa 960
 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
 305 310 315 320
 gtc aag gag gtc acg acg aat gat ggc gtc aca acc atc gct aat aac 1008
 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
 325 330 335
 ctt acc agc acg gtt caa gtc ttc tcg gac tcg gag tac cag ctt ccg 1056

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
 340 345 350
 tac gtc ctc ggc tct gcg cac cag ggc tgc ctc cct ccg ttc ccg gcg 1104
 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
 355 360 365
 gac gtg ttc atg att ccg caa tac ggc tac ctg acg ctc aac aat ggc 1152
 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
 370 375 380
 agc caa gcc gtg gga cgt tca tcc ttt tac tgc ctg gaa tat ttc cct 1200
 Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
 385 390 395 400
 tct cag atg ctg aga acg ggc aac aac ttt acc ttc agc tac acc ttt 1248
 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
 405 410 415
 gag gaa gtg cct ttc cac agc agc tac ggc cac agc cag agc ctg gac 1296
 Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
 420 425 430
 cgg ctg atg aat cct ctc atc gac caa tac ctg tat tac ctg aac aga 1344
 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
 435 440 445
 act caa aat cag tcc gga agt gcc caa aac aag gac ttg ctg ttt agc 1392
 Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
 450 455 460
 cgt ggg tct cca gct ggc atg tct gtt cag ccc aaa aac tgg cta cct 1440
 Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
 465 470 475 480
 gga ccc tgt tat cgg cag cag cgc gtt tct aaa aca aaa aca gac aac 1488
 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
 485 490 495
 aac aac agc aat ttt acc tgg act ggt gct tca aaa tat aac ctc aat 1536
 Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
 500 505 510
 ggg cgt gaa tcc atc atc aac cct ggc act gct atg gcc tca cac aaa 1584
 Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
 515 520 525
 gac gac gaa gac aag ttc ttt ccc atg agc ggt gtc atg att ttt gga 1632

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly			
530	535	540	
aaa gag agc gcc gga gct tca aac act gca ttg gac aat gtc atg att		1680	
Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile			
545	550	555	560
aca gac gaa gag gaa att aaa gcc act aac cct gtg gcc acc gaa aga		1728	
Thr Asp Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg			
565	570	575	
ttt ggg acc gtg gca gtc aat ttc cag agc agc aca gac cct gcg		1776	
Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala			
580	585	590	
acc gga gat gtg cat gct atg gga gca tta cct ggc atg gtg tgg caa		1824	
Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln			
595	600	605	
gat aga gac gtg tac ctg cag ggt ccc att tgg gcc aaa att cct cac		1872	
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His			
610	615	620	
aca gat gga cac ttt cac ccg tct ctt atg ggc ggc ttt gga ctc		1920	
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu			
625	630	635	640
aag aac ccg cct cct cag atc ctc atc aaa aac acg cct gtt cct gcg		1968	
Lys Asn Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala			
645	650	655	
aat cct ccg gcg gag ttt tca gct aca aag ttt gct tca ttc atc acc		2016	
Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr			
660	665	670	
caa tac tcc aca gga caa gtg agt gtg gaa att gaa tgg gag ctg cag		2064	
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln			
675	680	685	
aaa gaa aac agc aag ccg tgg aat ccc gaa gtg cag tac aca tcc aat		2112	
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn			
690	695	700	
tat gca aaa tct gcc aac gtt gat ttt act gtg gac aac aat gga ctt		2160	
Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu			
705	710	715	720
tat act gag cct ccg ccc att ggc acc cgt tac ctt acc cgt ccc ctg		2208	

WO 00/28061

PCT/US99/25694

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725 730 735

taa 2211

<210> 13
<211> 736
<212> PRT
<213> AAV-1

<400> 13
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
405 410 415

Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
435 440 445

Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
450 455 460

Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
485 490 495

Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
500 505 510

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
530 535 540

Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
545 550 555 560

Thr Asp Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
565 570 575

Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
580 585 590

Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
690 695 700

Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 705 710 715 720

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
 725 730 735

<210> 14
 <211> 1800
 <212> DNA
 <213> AAV-1

<220>
 <221> CDS
 <222> (1)...(1797)

<400> 14
 acg gct cct gga aag aaa cgt ccg gta gag cag tcg cca caa gag cca 48
 Thr Ala Pro Gly Lys Lys Arg Pro Val Glu Gln Ser Pro Gln Glu Pro
 1 5 10 15

gac tcc tcc tcg ggc atc ggc aag aca ggc cag cag ccc gct aaa aag 96
 Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys
 20 25 30

aga ctc aat ttt ggt cag act ggc gac tca gag tca gtc ccc gat cca 144
 Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Gln Ser Val Pro Asp Pro
 35 40 45

caa cct ctc gga gaa cct cca gca acc ccc gct gct gtg gga cct act 192
 Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro Ala Ala Val Gly Pro Thr
 50 55 60

aca atg gct tca ggc ggt ggc gca cca atg gca gac aat aac gaa ggc 240
 Thr Met Ala Ser Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly
 65 70 75 80

gcc gac gga gtg ggt aat gcc tca gga aat tgg cat tgc gat tcc aca 288
 Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr
 85 90 95

tgg ctg ggc gac aga gtc atc acc acc agc acc cgc acc tgg gcc ttg 336
 Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
 100 105 110

ccc acc tac aat aac cac ctc tac aag caa atc tcc agt gct tca acg 384
 Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr
 115 120 125

ggg gcc aac gac aac cac tac ttc ggc tac agc acc ccc tgg ggg	432		
Gly Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly			
130	135	140	
tat ttt gat ttc aac aga ttc cac tgc cac ttt tca cca cgt gac tgg	480		
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp			
145	150	155	160
cag cga ctc atc aac aac aat tgg gga ttc cgg ccc aag aga ctc aac	528		
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn			
165	170	175	
ttc aaa ctc ttc aac atc caa gtc aag gag gtc acg acg aat gat ggc	576		
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly			
180	185	190	
gtc aca acc atc gct aat aac ctt acc agc acg gtt caa gtc ttc tcg	624		
Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser			
195	200	205	
gac tcg gag tac cag ctt ccg tac gtc ctc ggc tct gcg cac cag ggc	672		
Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly			
210	215	220	
tgc ctc cct ccg ttc ccg gcg gac gtg ttc atg att ccg caa tac ggc	720		
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly			
225	230	235	240
tac ctg acg ctc aac aat ggc agc caa gcc gtg gga cgt tca tcc ttt	768		
Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe			
245	250	255	
tac tgc ctg gaa tat ttc cct tct cag atg ctg aga acg ggc aac aac	816		
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn			
260	265	270	
ttt acc ttc agc tac acc ttt gag gaa gtg cct ttc cac agc agc tac	864		
Phe Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr			
275	280	285	
gcg cac agc cag agc ctg gac cgg ctg atg aat cct ctc atc gac caa	912		
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln			
290	295	300	
tac ctg tat tac ctg aac aga act caa aat cag tcc gga agt gcc caa	960		
Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln			
305	310	315	320

aac aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt	1008		
Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val			
325	330	335	
cag ccc aaa aac tgg cta cct gga ccc tgg tat cgg cag cag cgc gtt	1056		
Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val			
340	345	350	
tct aaa aca aaa aca gac aac aac agc aat ttt acc tgg act ggt	1104		
Ser Lys Thr Lys Thr Asp Asn Asn Ser Asn Phe Thr Trp Thr Gly			
355	360	365	
gct tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc	1152		
Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly			
370	375	380	
act gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg	1200		
Thr Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met			
385	390	395	400
agc ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act	1248		
Ser Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr			
405	410	415	
gca ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act	1296		
Ala Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr			
420	425	430	
aac cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag	1344		
Asn Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln			
435	440	445	
agc agc agc aca gac cct gcg acc gga gat gtg cat gct atg gga gca	1392		
Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala			
450	455	460	
tta cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc	1440		
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro			
465	470	475	480
att tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct	1488		
Ile Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro			
485	490	495	
ctt atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc	1536		
Leu Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile			
500	505	510	

aaa aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca	1584		
Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr			
515	520	525	
aag ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg	1632		
Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val			
530	535	540	
gaa att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc	1680		
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro			
545	550	555	560
gaa gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt	1728		
Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe			
565	570	575	
act gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc	1776		
Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr			
580	585	590	
cgt tac ctt acc cgt ccc ctg taa	1800		
Arg Tyr Leu Thr Arg Pro Leu			
595			
<210> 15			
<211> 599			
<212> PRT			
<213> AAV-1			
<400> 15			
Thr Ala Pro Gly Lys Lys Arg Pro Val Glu Gln Ser Pro Gln Glu Pro			
1	5	10	15
Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys			
20	25	30	
Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu Ser Val Pro Asp Pro			
35	40	45	
Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro Ala Ala Val Gly Pro Thr			
50	55	60	
Thr Met Ala Ser Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly			
65	70	75	80
Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr			

85	90	95
----	----	----

Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu	100	105
---	-----	-----

110

Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr	115	120
---	-----	-----

125

Gly Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly	130	135
---	-----	-----

140

Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp	145	150
---	-----	-----

155

160

Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn	165	170
---	-----	-----

175

Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly	180	185
---	-----	-----

190

Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser	195	200
---	-----	-----

205

Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly	210	215
---	-----	-----

220

Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly	225	230
---	-----	-----

235

240

Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe	245	250
---	-----	-----

255

Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn	260	265
---	-----	-----

270

Phe Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr	275	280
---	-----	-----

285

Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln	290	295
---	-----	-----

300

Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln	305	310
---	-----	-----

315

320

Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val	325	330
---	-----	-----

335

Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val

340	345	350
-----	-----	-----

Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly		
355	360	365

Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly		
370	375	380

Thr Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met		
385	390	395

Ser Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr		
405	410	415

Ala Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr		
420	425	430

Asn Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln		
435	440	445

Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala		
450	455	460

Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro		
465	470	475

Ile Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro		
485	490	495

Leu Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile		
500	505	510

Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr		
515	520	525

Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val		
530	535	540

Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro		
545	550	555

Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe		
565	570	575

Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr		
580	585	590

Arg Tyr Leu Thr Arg Pro Leu

```

<210> 16
<211> 1605
<212> DNA
<213> AAV-1

<220>
<221> CDS
<222> (1)..(1602)

<400> 16
atg gct tca ggc ggt ggc gca cca atg gca gac aat aac gaa ggc gcc 48
Met Ala Ser Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala
1 5 10 15

gac gga gtg ggt aat gcc tca gga aat tgg cat tgc gat tcc aca tgg 96
Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp
20 25 30

ctg ggc gac aga gtc atc acc acc agc acc cgc acc tgg gcc ttg ccc 144
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
35 40 45

acc tac aat aac cac ctc tac aag cca atc tcc agt gct tca acg ggg 192
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly
50 55 60

gcc agc aac gac aac cac tac ttc ggc tac agc acc ccc tgg ggg tat 240
Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr
65 70 75 80

ttt gat ttc aac aga ttc cac tgc cac ttt tca cca cgt gac tgg cag 288
Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln
85 90 95

cga ctc atc aac aac aat tgg gga ttc cgg ccc aag aga ctc aac ttc 336
Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe
100 105 110

aaa ctc ttc aac atc caa gtc aag gag gtc acg acg aat gat ggc gtc 384
Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val
115 120 125

aca acc atc gct aat aac ctt acc agc acg gtt caa gtc ttc tcg gac 432
Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Val Gln Val Phe Ser Asp
130 135 140

```

tcg gag tac cag ctt ccg tac gtc ctc ggc tct gcg cac cag ggc tgc	480		
Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys			
145	150	155	160
ctc cct ccg ttc ccg gcg gac gtg ttc atg att ccg caa tac ggc tac	528		
Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr			
165	170	175	
ctg acg ctc aac aat ggc agc caa gcc gtg gga cgt tca tcc ttt tac	576		
Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr			
180	185	190	
tgc ctg gaa tat ttc cct tct cag atg ctg aga acg ggc aac aac ttt	624		
Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe			
195	200	205	
acc ttc agc tac acc ttt gag gaa gtg cct ttc cac agc agc tac gcg	672		
Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala			
210	215	220	
cac agc cag agc ctg gac cgg ctg atg aat cct ctc atc gac caa tac	720		
His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr			
225	230	235	240
ctg tat tac ctg aac aga act caa aat cag tcc gga agt gcc caa aac	768		
Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn			
245	250	255	
aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt cag	816		
Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln			
260	265	270	
ccc aaa aac tgg cta cct gga ccc tgt tat cgg cag cag cgc gtt tct	864		
Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser			
275	280	285	
aaa aca aaa aca gac aac aac agc aat ttt acc tgg act ggt gct	912		
Lys Thr Lys Thr Asp Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala			
290	295	300	
tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc act	960		
Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr			
305	310	315	320
gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg agc	1008		
Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser			
325	330	335	

ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act gca	1056		
Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala			
340	345	350	
ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act aac	1104		
Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn			
355	360	365	
cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag agc	1152		
Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser			
370	375	380	
agc agc aca gac cct ggg acc gga gat gtg cat gtc aat atg gga gca tta	1200		
Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu			
385	390	395	400
cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc att	1248		
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile			
405	410	415	
tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct ctt	1296		
Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu			
420	425	430	
atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc aaa	1344		
Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys			
435	440	445	
aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca aag	1392		
Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys			
450	455	460	
ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg gaa	1440		
Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu			
465	470	475	480
att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc gaa	1488		
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu			
485	490	495	
gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt act	1536		
Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr			
500	505	510	
gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc cgt	1584		
Val Asp Asn Asn Gly Leu Tyr Thr Glu Phe Arg Pro Ile Gly Thr Arg			
515	520	525	

tac ctt acc cgt ccc ctg taa 1605
 Tyr Leu Thr Arg Pro Leu
 530

<210> 17
 <211> 534
 <212> PRT
 <213> AAV-1

<400> 17
 Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala
 1 5 10 15

Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp
 20 25 30

Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
 35 40 45

Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly
 50 55 60

Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr
 65 70 75 80

Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln
 85 90 95

Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe
 100 105 110

Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val
 115 120 125

Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser Asp
 130 135 140

Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys
 145 150 155 160

Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr
 165 170 175

Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr
 180 185 190

WO 00/28061

PCT/US99/25694

Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe
195 200 205

Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala
210 215 220

His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr
225 230 235 240

Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn
245 250 255

Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln
260 265 270

Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser
275 280 285

Lys Thr Lys Thr Asp Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala
290 295 300

Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr
305 310 315 320

Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser
325 330 335

Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala
340 345 350

Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn
355 360 365

Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser
370 375 380

Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu
385 390 395 400

Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
405 410 415

Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu
420 425 430

Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys
435 440 445

Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys
450 455 460

Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
465 470 475 480

Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
485 490 495

Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr
500 505 510

Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg
515 520 525

Tyr Leu Thr Arg Pro Leu
530

<210> 18
<211> 4691
<212> DNA
<213> aav-2

<400> 18
ttggccactc cctctctgcg cyctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60
cgacgccccg gcttgcccg ggcggccctca gtgagcgagc gagcgcgcag agagggagtg 120
gc当地actcca tcactagggg tccctggagg ggtggatcg tgacgtgaat tacgtcatag 180
ggtagggag gtccctgtatt agaggtcactg tgagtgtttt gc当地atattt gc当地acccat 240
gtggtcacgc tgggtatata agcccgagtg agcacgcagg gtctccatatt tgaagcggga 300
ggtttgaacg cgc当地ccgatc atgcccgggt tttacgagat tggatatttgc当地ccagcg 360
accttgcacgg gcatctgccc ggc当地tctg acagctttgt gaactgggtg gccgagaagg 420
aatgggagtt gccc当地cagat tctgacatgg atctgaatct gattgagcag gc当地ccctga 480
ccgtggccga gaagctgcag cgc当地tgc tgacggaatg gccc当地gttg agtaaggccc 540
cgaggccct tttcttgcg caatttgcg agggagagag ctacttccac atgcacgtgc 600
tcgtggaaac caccggggtg aaatccatgg ttttgggacg tttcctgagt cagattcgcg 660
aaaaactgat tcagagaatt taccgcggga tcgagccgac tttgccaaac tggttcgcgg 720

tcacaaagac cagaaatggc gccggaggcg ggaacaaggt ggtggatgag tgctacatcc 780
ccaaattactt gctccccaaa acccagectg agctccagtg ggctggact aatatggAAC 840
agtatttaag cgccctgtttg aatctcacgg agcgtaaacg gttggggcg cagcatctga 900
cgcacgtgtc gcagacgcag gacgagaaca aagagaatca gaatcccaat tctgatgcgc 960
cggtgatca gatcaaaaact tcagccaggt acatggagct ggtgggggg ctcgtggaca 1020
aggggattac ctcggagaag cagtgatcc aggaggacca ggcttcatac attccttca 1080
atgcggcctc caactcgccg tcccaatca aggctgcctt ggacaatgcg ggaaagatata 1140
tgagcctgac taaaaccgccc cccgactacc tggggggca gcagccctgt gaggacattt 1200
ccagcaatcg gatttataaa attttggAAC taaacgggtt cgtatcccaa tatgcggctt 1260
ccgtctttctt gggatggggcc acgaaaaagt tcggcaagag gaacaccatc tggctgtttg 1320
ggcctgcaac taccgggaag accaacatcg cggaggccat agcccacact gtgccttct 1380
acgggtgcgt aaactggacc aatgagaact ttcccttcaa cgactgtgtc gacaagatgg 1440
tgatctggtg ggaggagggg aagatgaccg ccaagggtcggt ggagtccggcc aaagccattc 1500
tcggaggaag caaggtgcgc gtggaccaga aatgcggctt ctcggccctt atagacccga 1560
ctccccgtgat cgtcacctcc aacaccaaca tggcgccgt gattgacggg aactcaacga 1620
ccttcgaaca ccagcagccg ttgcaagacc ggatgttcaa atttgaactc acccccccgtc 1680
tggatcatga ctttgggaag gtcaccaagc aggaagtcaa agacttttc cggtggcaaa 1740
aggatcacgt gtttgagggtg gagcatgaat tctacgtcaa aaagggtgga gccaagaaaa 1800
gaccggcccc cagtgacgca gatataagtgc agcccaacg ggtgcgcgag tcagttgcgc 1860
agccatcgac gtcagacgcg gaagcttgcg tcaactacgc agacaggtac caaaacaaat 1920
gttctcgta cgtgggcattt aatctgtatgc tggccctgt cagacaatgc gagagaatga 1980
atcagaatttcc aatatctgc ttcaactacgc gacagaaaga ctgttttagag tgctttcccg 2040
tgtcagaatc tcaaccgggtt tctgtcgta aaaaaggcgta tcagaaactg tgctacattc 2100
atcatatcat gggaaagggtg ccagacgcgtt gcaactgcgtt cgtatctgggtc aatgtggattt 2160

tggatgactg catcttgaa caataaatga tttaaatcg gtatggctgc cgatggttat 2220
cttccagatt ggctcgagga cactctctct gaaggaataa gacagtggtg gaagctcaaa 2280
cctggcccac caccaccaaa gccccagag cggcataagg acgacagcag gggtcttgc 2340
cttcctgggt acaagtgactt cggacccttc aacggactcg acaagggaga gccggtaaac 2400
gaggcagacg ccgcggccct cgagcacgac aaagcttacg accggcagct cgacagcgg 2460
gacaacccgt acctcaagta caaccacgac gacgcggagt ttcaggagcg cttaaagaa 2520
gatacgtctt ttggggcaa cctcgacga gcagtcttc aggcgaaaaa gagggttctt 2580
gaacctctcg gcctgggtga ggaacctgtt aagacggctc cgggaaaaaa gaggccggta 2640
gaggactctc ctgtggagcc agactcctcc tcggaaaccg gaaagccgg ccagcagcct 2700
gcaagaaaaa gattgaattt tggtcagact ggagacgcag actcgttacc tgaccccccag 2760
cctctcgac agccaccagc agccccctctt ggtctggaa ctaatacgat ggctacaggc 2820
agtggcgcac caatggcaga caataacgag ggcgcggacg gagtggtaa ttccctccgg 2880
aattggcatt gcgattccac atggatgggc gacagagtca tcaccaccag caccgaaacc 2940
tggccctgc ccacctacaa caaccacctc tacaaacaaa ttccagecca atcaggagcc 3000
tcgaacgaca atcactactt tggctacagc accccttggg ggtatttga cttaacaga 3060
ttccactgcc acttttccacc acgtgactgg caaagactca tcaacaacaa ctggggattc 3120
cgacccaaga gactcaactt caacctcttt aacattcaag tcaaagaggt cacgcagaat 3180
gacggtaacgca cgacgattgc caataaacctt accagcacgg ttcaagggtt tactgactcg 3240
gagtaaccaggc tccctgtacgt cctcggtcg ggcgtcaag gatgcctccc gccgttccca 3300
gcagacgtct tcatggtgcc acagtatggc tacctcaccc tgaacaacgg gagtcaggca 3360
gttaggacgct cttcatttttta ctgcctggag tactttccctt ctcagatgct gcgtaccgg 3420
aacaacttta cttcagcta cactttttag gacgtttccctt tccacagcag ctacgctcac 3480
agccagagtc tggaccgtct catgaatcct ctcacgacc agtacctgtt ttacttgagc 3540
agaacaaaca ctccaaagtgg aaccaccacg cagtcaaggc ttcaagggttccca 3600

gcccagtgaca ttccgggacca gtccttaggaac tggcttcctg gaccctgtta ccggccagcac 3660
cgagttatgaa agacatctgc ggataacaac aacagtgaat actcgtggac tggagctacc 3720
aagtaccacc tcaatggcag agactctctg gtgaatccgg ggccccccat ggcaagccac 3780
aaggacgatg aagaaaagtt ttttcctcag agcggggttc tcatcttgg gaagcaaggc 3840
tcagagaaaa caaatgtgaa cattgaaaag gtcatgatta cagacgaaga ggaaatccca 3900
acaaccaatc ccgtggctac ggagcagtat ggttctgtat ctaccaacct ccagagaggc 3960
aacagacaag cagctaccgc agatgtcaac acacaaggcg ttcttcagg catggtctgg 4020
caggacagag atgtgtacct tcaggggccc atctggcaa agattccaca cacggacgga 4080
cattttcacc cctctccct catgggtgga ttccggactta aacaccctcc tccacagatt 4140
ctcatcaaga acaccccggt acctgcgaaat ctttcgacca ctttcagtgc ggcaaagttt 4200
gcttccttca tcacacagta ctccacggga cacggtcagc gtggagatcg agtgggagct 4260
cgagaacgaa aacagcaaac gctggaatcc cgaaattcag tacacttcca actacaacaa 4320
gtctgttaat cgtrggacttt accgtggata ctaatggcgt gtattcagag cctcgccccca 4380
ttggcaccag atacctgact cgtaatctgt aattgcttgc taatcaataa accgtttaat 4440
tcgtttcagt tgaacttgg tctctgcgtt ttttttctt atcttagtttc catggctacg 4500
tagataagta gcatggcggg ttaatcatta actacaagga accccttagtg atggagttgg 4560
ccactccctc tctgcgcgtc cgctcgctca ctgaggccgg gcgaccaaag gtcgccccac 4620
gccccggctt tgccccggcg gcctcagtga gcgagcggc gcgagcagag ggagtggca 4680

a

4681

<210> 19
<211> 4683
<212> DNA
<213> aav-6

<400> 19
ttggccactc cctctctgcg cgctcgctcg ctcaactgagg ccggggcacc aaaggctgcc 60

cgacgcccgg gctttgcccgg ggcggccctca gtgagcgagc gagcgcgcag agagggagtg 120
gccaactcca tcactagggg ttcctggagg ggtggagtgcg tgacgtaat tacgtcatag 180
ggtagggag gtcctgtatt agaggtcacg tgagtgttt gcgacatttt gcgacaccat 240
gtggtcacgc tgggtatata agcccgagtg agcacgcagg gtctccattt tgaagcggga 300
ggtttaacg cgcagcgcctca tgccggggttt ttacgagatt gtattaagg tccccagcga 360
ccttgacgag catctgcccgg gcatttctga cagctttgtg aactgggtgg ccgagaagga 420
atgggagttg ccgcagatt ctgacatgga tctgaatctg attgagcagg caccctgac 480
cgtggccgag aagctgcagc gcgacttccct ggtccactgg cgccgcgtga gtaaggcccc 540
ggaggccctc ttctttgttc agttcgagaa gggcgagtcc tacttccacc tccatattct 600
ggtagggagacc acgggggtca aatccatgtt gctggggcgc ttccctgagtc agattagcga 660
caagctggtg cagaccatct accgcgggat cgagccgacc ctgcccaact ggttcgcggt 720
gaccaagacg cgtaatggcg ccggaggggg gaacaagggtg gtggacgagt gctacatccc 780
caactacctc ctgcccaaga ctcagcccgaa gctgcagtgg qcgtggacta acatggagga 840
gtatataagc gcgtgtttaa acctggccga gcgcacacgg ctcgtggcgc aegacctgac 900
ccacgtcagc cagaccagg agcagaacaa ggagaatctg aaccccaattt ctgacgcgcc 960
tgtcatccgg tcaaaaacctt ccgcacgcta catggagctg gtcgggtggc tggtagggacc 1020
gggcatcacc tccgagaagc agtggatcca ggaggaccag gcctcgata tctccttcaa 1080
cgccgcctcc aactcgccgt cccagatcaaa ggccgcctcg gacaatgcgc gcaagatcat 1140
ggcgctgacc aaatccgcgc ccgactacctt ggtggccccc gctccgcggcccg ccgacattaa 1200
aaccacccgc atttacccgca tccctggagctt gaaacggctac gaccctgcct acgcccggctc 1260
cgctttctc ggctggggcc agaaaagggtt cggaaaacgc aacaccatct ggctgtttgg 1320
ggccgcacc acggcaaga ccaacatcgc ggaagccatc gcccacgcgg tgccttcta 1380
cggtcgctc aactggacca atgagaactt tcccttcaac gattgcgtcg acaagatgg 1440
gatctggtgg gaggaggcga agatgacggc caaggtcgat gatccgcac aggcattct 1500

cgccggcagc aagggtgcgcg tggaccaaaa gtgcaagtgc tccgcccaga tcgatcccac 1560
ccccgtgate gtcacactcca acaccaacat gtgcgcgcgtg attgacggga acagcaccac 1620
cttcgagcac cagcagccgt tgcaggaccg gatgttcaaa tttaactca cccgcccgtct 1680
ggagcatgac ttggcaagg tgacaaagca ggaagtcaaa gagttttcc gctggcgca 1740
ggatcacgtg accggagggtgg cgcatgagtt ctacgtcaga aagggtggag ccaacaacag 1800
acccggccccc gatgacgcgg ataaaagcga gcccaagcgg gcctgcccct cagtcgcgg 1860
tccatcgacg tcagacgcgg aaggagctcc ggtggacttt gccgacaggt accaaaacaa 1920
atgttctcgta cacgcgggca tgcttcagat gctgtttccc tgcaaaacat gcgagagaat 1980
gaatcagaat ttcaacattt gcttcacgca cgggaccaga gactgttcag aatgtttccc 2040
cgccgtgtca gaatctcaac cggtcgtcag aaagaggacg tatacgaaac tctgtgccat 2100
tcatcatctg ctggggcgccc ctcccgagat tgcttcgtcg gcctgcgtc tggtcaacgt 2160
ggatctggat gactgtgttt ctgagcaata aatgacttaa accaggtatg gctgcccgt 2220
gttatcttcc agattggctc gaggacaacc tctctgaggg cattcggcag tgggtggact 2280
tgaaacctgg agccccgaaa cccaaagcga accagcaaaa gcaggacgac ggccggggtc 2340
tggtgcttcc tggctacaag tacctcggac cttcaacgg actcgacaaag ggggagcccg 2400
tcaacgcggc ggtatgcagcg gcccctcgagc acgacaaggc ctacgaccag cagctcaaaag 2460
cggttgacaa tccgtacctg cggataacc acgcccacgc cgagtttcag gagcgtctgc 2520
aagaagatac gtctttggg ggcaacctcg ggcgagcagt ctccaggcc aagaagaggg 2580
ttctcgaacc ttttggtctg gttgaggaag gtgctaagac ggctcctgga aagaaacgtc 2640
cggttagagca gtcgccacaa gagccagact cttccctcggg cattggcaag acaggccacg 2700
agcccgctaa aaagagactc aattttggtc agactggcga ctcagagtca gtccccgacc 2760
cacaacctct cggagaacct ccagcaaccc cccgtgtctgt gggacctact acaatggctt 2820
caggcgggtgg cgcaccaatg gcagacaata acgaaggcgc cgacggagtg ggtaatgcct 2880
cagggaaatttgcatttgcat tccacatggc tggcgacag agtcatcacc accagcaccc 2940

gaacatggc cttgcccacc tataacaacc acctctacaa gcaaatctcc agtgcttcaa 3000
cgggggccag caacgacaac cactactcg gctacagcac cccctgggg tatttgatt 3060
tcaacagatt ccactgcccatttctaccac gtgactggca gcgactcata aacaacaatt 3120
ggggattccg gcccaagaga ctcaacttca agctcttcaa catccaagtc aaggaggtca 3180
cgacgaatga tggcgtaacg accatcgta ataaaccttac cagcacgggtt caagtcttgt 3240
cggactcggta gtaccagttc ccgtacgtcc tcggctctgc gcaccaggc tgccctccctc 3300
cggtcccgcc ggacgtgttc atgatccgcg agtacggcta cctaacgctc aacaatggca 3360
gccaggcagt gggacgctca tcctttact gccttggata ttcccatcg cagatgtga 3420
gaacggcaa taactttacc ttcaacttaca cttcgagga cgtgccttc cacagcagct 3480
acgcgcacag ccagagcctg gaccggctga tgaatccctt catcgaccag tacctgtatt 3540
acctgaacag aactcacaat cagtcggaa gtgcccaaaa caaggacttg ctgtttagcc 3600
gtgggtctcc agctggcatg tctgttcagc ccaaaaactg gctaccttggaa ccctgttacc 3660
ggcagcagcg cgtttctaaa acaaaaacag acaacaacaa cagcaactt acctggactg 3720
gtgcctcaaa atataacctt aatgggcgtg aatctataat caaccctggc actgctatgg 3780
cctcacacaa agacgacaaa gacaaggctt ttcccatgag cggtgtcatg atttttggaa 3840
aggagagcgc cggagcttca aacactgcat tggacaatgt catgatcaca gacgaagagg 3900
aaatcaaagc cactaaccctt gtggccacccg aaagatttgg gactgtggca gtcaatctcc 3960
agagcagcag cacagaccctt gcgaccggag atgtgcatgt tatgggagcc ttacctggaa 4020
tgggtgtggca agacagagac gtataccctgc agggtcctat ttggccaaaa attcctcaca 4080
cgatggaca ctttaccccg tctcccttca tggcggctt tggacttaag caceccgcctc 4140
ctcagatcctt catcaaaaac acgcctgttc ctgcgaatcc tccggcagag tttcggctta 4200
caaagtttgc ttcatccatc acccagtattt ccacaggaca agtgagcgtg gagattgaat 4260
gggagctgca gaaagaaaac agcaaacgct ggaatcccga agtgagcgtat acatctaact 4320
atgcaaaaatc tgccaaacgtt gatttcactg tggacaacaa tggactttat actgagcctc 4380

WO 00/28061

PCT/US99/25694

gccccattgg cacccgttac ctcacccgtc ccctgttaatt gtgtgttaat caataaaccg 4440
gttaattcgt gtcagttgaa ctttggtctc atgtccttat tatcttatct ggtcaccata 4500
gcaaccgggtt acacattaac tgcttagttg cgcttcgcga atacccctag tgatggagtt 4560
gcccactccc tctatgcgcg ctcgctcgct cgggtggggcc ggcagagcag agctctgcgg 4620
tctcgccgacc tttggtccgc aggccccacc gagcgagcga ggcgcgcatacg agggagtgcc 4680

caa

4683

<210> 20
<211> 16
<212> DNA
<213> rep binding motif

<400> 20
gctcgctcgc tcgcgtg

16

INTERNATIONAL SEARCH REPORT

Int. Jpn Application No
PCT/US 99/25694

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/86 C12N15/35 C12N5/10 A61K48/00													
According to International Patent Classification (IPC) or to both national classification and IPC													
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K													
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched													
Electronic data base consulted during the International search (name of data base and, where practical, search terms used)													
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;"> RUTLEDGE E. A. ET AL.: "Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2." JOURNAL OF VIROLOGY, vol. 72, no. 1, January 1998 (1998-01), pages 309-319, XP002137089 ISSN: 0022-538X cited in the application the whole document </td> <td style="text-align: center; padding: 2px;">1-23</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;"> WO 98 11244 A (SAFER BRIAN ;US HEALTH (US); CHIORINI JOHN A (US); KOTIN ROBERT M) 19 March 1998 (1998-03-19) the whole document </td> <td style="text-align: center; padding: 2px;">1-23</td> </tr> <tr> <td style="text-align: center; padding: 2px;"></td> <td style="text-align: center; padding: 2px;">-/-</td> <td style="text-align: center; padding: 2px;">-/-</td> </tr> </tbody> </table>		Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	RUTLEDGE E. A. ET AL.: "Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2." JOURNAL OF VIROLOGY, vol. 72, no. 1, January 1998 (1998-01), pages 309-319, XP002137089 ISSN: 0022-538X cited in the application the whole document	1-23	Y	WO 98 11244 A (SAFER BRIAN ;US HEALTH (US); CHIORINI JOHN A (US); KOTIN ROBERT M) 19 March 1998 (1998-03-19) the whole document	1-23		-/-	-/-
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.											
Y	RUTLEDGE E. A. ET AL.: "Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2." JOURNAL OF VIROLOGY, vol. 72, no. 1, January 1998 (1998-01), pages 309-319, XP002137089 ISSN: 0022-538X cited in the application the whole document	1-23											
Y	WO 98 11244 A (SAFER BRIAN ;US HEALTH (US); CHIORINI JOHN A (US); KOTIN ROBERT M) 19 March 1998 (1998-03-19) the whole document	1-23											
	-/-	-/-											
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.													
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the International filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the International filing date but later than the priority date claimed *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family													
Date of the actual completion of the International search 8 May 2000													
Date of mailing of the International search report 22/05/2000													
Name and mailing address of the ISA European Patent Office, P.B. 6816 Petelaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 espn Fax: (+31-70) 340-3018													
Authorized officer Mandl, B													

INTERNATIONAL SEARCH REPORT

Int. Search Application No.
PCT/US 99/25694

C(continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	XIAO W. ET AL.: "Gene therapy vectors based on adeno-associated virus type 1." JOURNAL OF VIROLOGY, vol. 73, no. 5, May 1999 (1999-05), pages 3994-4003, XP002137090 ISSN: 0022-538X the whole document	1-23

INTERNATIONAL SEARCH REPORT

...international application No.
PCT/US 99/25694

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 18-20 and 22, as far as an *in vivo* application is concerned, are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims No.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims No.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Search Application No
PCT/US 99/25694

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9811244 A	19-03-1998	AU 4645697 A		02-04-1998
		EP 0932694 A		04-08-1999